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1 Summary 
 
1.1 Local control of TH action in cancer growth and stemness 
Non-melanoma skin cancers, including basal cell carcinoma (BCC), are keratinocyte-
derived tumors, which represent the most frequent cancers worldwide. BCCs can cause 
significant tissue destruction by local invasion, which is particularly devastating since 
they usually develop in regions closed to the eyes, nose and ears. The aberrant 
Hedgehog (Hh) pathway is a pivotal defect implicated in BCC formation. Several 
studies have demonstrated functional cross-talk between thyroid hormone (TH) and Hh 
signaling. TH controls a number of cellular processes including cell proliferation, 
differentiation and survival/apoptosis. Intracellular TH concentration is not simply the 
mirror of circulating TH levels, but is determined by a balance between the activating 
and inactivating deiodinases enzymes, D2 and D3. In functional combinations, these 
regulatory molecules provide the ability to fine-tune TH action at cell level. TH 
deregulation is frequent in human tumors, in particular type 3 iodothyronine deiodinase 
(D3), the thyroid hormone (TH)-inactivating enzyme, is an oncofetal protein rarely 
expressed in adult life, but re-activated in proliferating and neoplastic contexts. By 
terminating TH action within the tumor microenvironment, D3 enhances cancer cell 
proliferation. We aimed to understand how the TH action regulates multiple aspects of 
tumorigenesis, ranging from cancer formation to progression.  
Here we describe reciprocal regulation between TH action and the cancer-associated 
microRNA-21 (miR21) in BCC skin tumors. We found that, besides being negatively 
regulated by TH at transcriptional level, miR21 attenuates the TH signal by increasing 
D3 levels. The ability of miR21 to positively regulate D3 was mediated by GRHL3, a 
tumor suppressor gene and a hitherto unrecognized D3 transcriptional inhibitor. 
Moreover, we found that keratinocyte-specific D3-depletion significantly reduced 
tumor growth in a BCC mouse model, which establishes the functional relevance of this 
network in vivo. A second aim of this study was to underscore the role of TH and 
deiodinase D3 in the control of skin CSCs behavior. In vivo and in vitro evidences 
demonstrate that TH represses the transcription of the stemness gene Sox9. 
Furthermore, D3-depletion causes a variation of number of CD34+ cells demonstrating 
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that TH metabolism is important not only for the control of tumor growth and 
maintenance, but also for the behavior of CSCs. 
Elucidating the functional role of TH in the landscape of tumorigenesis is crucial for the 
use of hormonal regulation as a new tool in a therapeutic context. 
 
 
1.2 Il controllo locale dell’azione dell’OT nella crescita tumorale e nella staminalità 
I tumori cutanei non melanomatosi, tra cui i carcinomi basocellulari (o basaliomi), sono 
tumori di derivazione cheratinica, che rappresentano uno dei tipi di cancro più diffusi al 
mondo. Il basalioma è un tumore ad invasione locale ma può essere deturpante in 
quanto insorge generalmente in prossimità di occhi, naso ed orecchie. La principale 
causa del basalioma è un aberrante espressione del pathway di Hedgehog (Hh). Diversi 
studi hanno dimostrato l’esistenza di un cross-talk tra l’ormone tiroideo (OT) e il 
pathway di Hedgehog. L’OT controlla una serie di processi cellulari tra cui la 
proliferazione, il differenziamento ed i meccanismi di sopravvivenza/apoptosi. La 
concentrazione intracellulare dell’OT non rispecchia semplicemente i livelli circolanti 
di OT, ma è determinata da un equilibrio tra l'attivazione e inattivazione dell’ormone 
stesso mediata da due enzimi, D2 e D3. Il complesso sistema delle desiodasi svolge, 
quindi, un ruolo fondamentale nel regolare la quantità di ormone tiroideo a livello 
cellulare. Molti tumori sono influenzati dal signaling dell’ormone tiroideo, in 
particolare, la desidodasi di tipo 3, ovvero l’inattivatore dell’OT, è una proteina 
oncofetale raramente espressa nell’adulto, ma che viene riattivata in contesti di iper-
proliferazione e trasformazione neoplastica. Terminando l'azione dell’OT all'interno del 
microambiente tumorale, D3 aumenta la proliferazione delle cellule cancerose. Lo 
scopo principale del presente lavoro è stato quello di comprendere come l'azione 
dell’OT potesse regolare i molteplici aspetti della tumorigenesi, che vanno dalla 
formazione del cancro alla sua progressione. 
Abbiamo dimostrato l’esistenza di una reciproca interazione tra l’azione dell’OT e il 
microRNA-21 (miR21) nel basalioma. Abbiamo, infatti, scoperto che, oltre ad essere 
regolato negativamente dall’OT a livello trascrizionale, il miR21 attenua il segnale 
dell’OT aumentando i livelli di D3. La capacità di miR21 di regolare positivamente D3 
è mediata da GRHL3, un gene soppressore del tumore nonché un inibitore trascrizionale 
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di D3, fino a ad oggi sconosciuto. Inoltre, abbiamo dimostrato che, la deplezione di D3 
specificatamente in cheratinociti, riduce significativamente la crescita tumorale in un 
modello murino di basalioma, sottolineando l'importanza funzionale di questa rete in 
vivo. Un secondo scopo di questo lavoro è stato indagare gli effetti dell’OT e della D3 
nella regolazione delle CSCs della pelle. I nostri dati hanno dimostrato che l’OT 
reprime la trascrizione del gene Sox9 coinvolto nella staminalità delle cellule epiteliali. 
Inoltre, la deplezione di D3 provoca una variazione del numero di cellule CD34+ 
dimostrando che il metabolismo dell’OT è importante per il controllo della crescita 
tumorale e il mantenimento delle cellule staminali cancerose. Chiarire il ruolo 
funzionale dell’OT durante la tumorigenesi è di cruciale importanza per l'uso della 
regolazione ormonale come un nuovo strumento in contesti terapeutici. 
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2 Introduction 
 
2.1 Basal cell carcinoma and Shh signaling 
Basal cell carcinoma (BCC) is the most common cutaneous cancer of epithelial origin 
and account for approximately 80% of all non-melanoma skin cancer. One of principal 
etiological factors in the development of BCC is the exposure to the ultraviolet (UV) 
fraction of sun light (1). Areas of body that are exposed to sun are more prone to 
develop BCC; in fact about 90% are located in the head and neck region, with a 
particular predilection for the upper central part of the face. However, there are 
additional etiological factors, which play a role in the development of BCC as injury to 
the skin by X-ray, chronic inflammation, congenital malformations and genetic 
alterations such as point mutations in the Ras-oncogene (2). BCC is most common in 
Causasian population and rarely affects black- and other dark skinned population. The 
clinical forms of BCC are extremely variable: nodulo-ulcerative, superficial, 
morpheaform, pigmented, fibroadenoma. (3). The nodulo-ulcerative lesions are the 
most common type, accounting for 75% of cases of BCC. The typical clinical 
appearance is a well-circumscribed nodule or plaque with pearly border and overlying 
telangiectasia and may be combined with rodent ulcer. Superficial BCC represents 
about 10% of BCC. The clinical presentation is discrete erythematous macules or 
plaques with scaly change and a thin rolled border (3). BCC tends to share the common 
histopathologic features of a predominant basal cell type, peripheral palisading of 
lesional cell nuclei, and a mucinous stroma with artificial cleft between the epithelial 
island and the stroma. In addition, there are variable degrees of cytologic atypia and 
mitotic activity. 
The incidence of BCC is 30% higher in man than in women and the age is further most 
important factor influencing incidence. Person aged higher then 55 years have a 100-
fold hiegher incidence of BCC than persons of age below 20 years. BCC usually does 
not metastasize. In fact, rate of metastasis in BCC have been estimated as 0,1%,	 (4) 
however this malignancy can be very aggressive due to a highly infiltrate and invasive 
growth pattern by direct extension into adjacent tissue, leading to a severe destruction of 
affected skin. Especially in the case of facial BCC, the growth characteristic can be 
highly disfiguring and is therefore associated with severe morbidity (Fig. 2.1).  
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The origin of the cells which forms BCC is not yet entirely defined but the aberrant 
Hedgehog (Hh) pathway is a pivotal defect implicated in BCC formation. (5-7). In a 
silent Hedgehog pathway, where the Hh peptide is absent, the transmembrane receptor 
Patched-1 (Ptch1) is exerting an inhibitory action on another trasmembrane protein 
Smoothened (Smo) that is a key activator of the Gli pathway. In this situation, the Gli 
proteins are retained to the cytoplasm. In the opposite situation, when the Hh signal 
peptide is present and binds to and inactivates Ptch1 (or when Ptch1 inactivation is due 
to a loss of function mutation), Smo is no longer controlled by Ptch1 thereby activating 
Gli factors that translocate to the nucleus and induce transcription of Hh target genes 
(Fig. 2.2) (8). Uncontrolled activation of this pathway results in such cancers, as brain, 
muscle, skin and gastro-intestinal tract cancers. In particular, aberrant Hh pathway 
signaling has been detected in patients with nevoid BCC syndrome as well as in over 
95% of patients with sporadic BCCs. The Hh signaling has been shown to play a critical 
role not only in embryonic development, but also in other normal processes, such as 
Figure 2.1 Typical appearances and 
characteristics of basal cell 
carcinoma lesions 
A. Nodular, with small blood vessels 
on surface and pearly appearance; B. 
Morpheaform with rolled-raised 
border; C. Nodulo-ulcerative, with 
erosion and breackdown of the skin; D. 
fibroadenoma. 	
A 
B 
C D 
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regulation of stem cells and maintenance of tissue homeostasis	 (9). The initial 
association between the Hh pathway and human cancers was made as a result of the 
discovery that loss-of-function mutations in human Ptch1 are associated with Gorlin 
syndrome, a rare and hereditary disorder. Patients with Gorlin syndrome show a broad 
spectrum of developmental defects and have a predisposition to develop basal cell 
carcinoma (BCC) and medulloblastoma (10). It was found that sporadic BCCs also have 
a high frequency of loss-of-function mutations in Ptch1 and, to a lesser extent, 
activating mutations in SMO. Notably, the downstream effectors of the Hh pathway 
(Gli1/2/3) are rarely found to be mutated in sporadic BCCs. Inactivating mutations in 
Ptch1 occur in about 70%–80% of BCCs, and they mostly produce a truncated protein 
or are frameshift or missense mutations (11,	12). In another fraction of BCCs, activation 
of Hh signaling results from gain-of-function mutations in SMO (about 6%–21%). 
Based on these informations, in the last few years, several mouse models using tissue-
specific activation of the Hh pathway have provided a powerful tool to investigate the 
mechanisms of Hh-mediated development of BCC and to identify the BCC cell of 
origin. All current BCC mouse models target different components of Hh signaling, 
from the Shh ligand, to the transmembrane proteins Ptch1 and Smo, and the Gli 
transcription factors. Because homozygous Ptch1 knockdown leads to embryonic 
lethality due to heart and neural tube closure defects, skin-specific knockout of Ptch1 
has been generated, under the promoter of keratin 14 (K14CRE), keratin 5 (K5CRE), or 
keratin 6a (K6aCRE). In addition to Ptch1 inactivation, skin-specific knockin SmoM2 
mice (K14CRE-ER/Rosa26-SmoM2) develop multiple BCCs	 (13,	 14). Furthermore, 
overexpression of Gli2 in mouse skin leads to development of BCC (15). In this context 
it is important to note that tumors developing in the mouse may not always fully mimic 
human BCCs but represent various stages in a spectrum of benign to malignant Hh 
pathway– induced BCC-like tumors, likely reflecting a similar variation in humans, 
where benign hamartomas and BCCs appear to be driven by different levels of Hh 
pathway activation (16). 
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2.2 Mechanism of thyroid hormone action and deiodinases 
Thyroid hormone (TH) is a pleiotropic agent that controls the development and 
homeostasis of several organs in vertebrates. It is produced for ~ 90% by the thyroid 
gland in the form of the biologically inactive precursor thyroxine (T4) and its action is 
initiated by the activation of T4 into T3, catalyzed by two seleno-proteins, the type 1 or 
type 2 iodothyronine deiodinase (D1 or D2). Both, T4 and T3 undergo inner ring 
deiodination, catalyzed by another seleno-protein, type 3 deiodinase (D3), generating 
inactive metabolites that do not interact with T3 receptors, reverse triiodothyronine 
(rT3) and 3,3’-diiodothyronine (T2), respectively (17). Therefore, depending on 
whether the deiodination occurs on the inner (IDR) or outer ring (ODR) of the 
iodothyronine substrate, the deiodination results in activating pathway or inactivating 
pathway. In fact, while ~ 20% of T3 is secreted by the thyroid, most of T3 is derived 
Figure 2.2 Schematic representation of Hedgehog signaling pathway 
A. In the absence of Hh ligand, the Gli transcription factors are bound to a multiprotein 
complex with the negative regulator Sufu. Phosphorylation of Gli by PKA, GSK3β and CK1 
targets Gli proteins to proteasome; B. Upon binding of Hh ligand to its receptor Ptch, Ptch 
loose its ability to inhibit Smo, which moves into the citoplasm, thus stimulating the pathway 
and preventing Gli cleavage. The activated forms of Gli bind to Gli-promoters in the nucleus 
and stimulate transcription of target genes (Silvia Pandolfi and Basbara stecca 2015). 
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from outer ring deiodination of T4 in peripheral tissue where the actions of these three 
deiodinases, together with the uptake of T3 and T4 into the cell by several specific 
transporters (organic anion trasporter 2 and 3, Oatp2 and Oatp3, and monocarboxylate 
transporter 8 and 10, MCT8 and MCT10) (18), determine the levels of T3 availability 
and constitute a potent mechanism of pre-receptor control of TH action at cellular level, 
regardless of the constant plasma T3 levels (Fig. 2.3). Therefore, access to the 
intracellular compartment is mediated by four different families of transport proteins 
that have been shown to be involved in the traffic of iodothyronines across the plasma 
membrane, with different patterns of tissue expression (19). The monocarboxylate 8 
(MCT8) is probably the most relevant transporter as mutations in the MCT8 protein 
have been associated with variable levels of mental retardation in humans combined 
with lack of speech development, muscle hypotonia and endocrine dysfunctions (19, 
20). Once the active hormone T3 is present inside the cells, it can enter the nucleus and 
reach the TRs, a family of ligand-dependent transcription factors that enhance or inhibit 
the expression of target genes by binding to specific DNA sequences, known as TH 
response elements (TREs). Thyroid hormone receptors exist in two isoforms, TRα and 
TRβ, which are encoded by the THRA and THRB genes, respectively (21). As already 
mentioned, the modern paradigm of thyroid hormone action recognizes that D2 and D3 
play antagonistic roles in a number of settings, with D2 increasing thyroid hormone 
signaling and D3, silencing it, independently of plasma T4 or T3. Thus, at any given 
moment, thyroid hormone signaling in different tissues and cells can be amplified or 
dampened, according to the local expression of deiodinases (17). The cloning of all 
three deiodinases identified the presence of the rare amino acid selenocysteine (Sec) 
located in the catalytic site (22). Like with the other selenoproteins, deiodinases 
undergo a unique synthetic mechanism that involves reprogramming of the stop codon, 
UGA, to a Sec amino acid (23). This takes place with a coordinated effort between the 
ribosomal machinery and an evolutionary conserved stem loop-shaped RNA element 
that is found at the 3’UTR of all mammalian selenocysteine proteins (23). This element 
is called the selenocysteine insertion sequence (SECIS) and functions as a binding site 
of several accessory proteins that recruit a Sec-charged tRNA and mediates the anti-
termination at the UGA codon. This allows the incorporation of a Sec molecule into the 
selenoprotein growing polypeptide chain. All three deiodinases are integral membrane 
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proteins of 29-33kDa that share an overall 50 % sequence similarity (24) and are 
homodimers whose dimerization is required for full catalytic activity (25,	 26).	 The 
subcellular localization varies among the three enzymes, and this affects their systemic 
versus cellular contributions to TH homeostasis (27). D1 is the only selenodeiodinase 
that can function as either an outer- (5’) or an inner (5)-ring iodothyronine deiodinase 
mainly in the liver, kidney and thyroid and was the first to be cloned (23,	28). For its 
tissue-specific expression, D1 contributes to the regulation of systemic T3 levels, by 
providing a significant portion of the circulating plasma T3 in euthyroid vertebrates. D1 
is an enzyme with a low kinetic efficiency, but its ability to dehalogenate iodine 
metabolites suggests that could also act as a scavenger enzyme that recycle iodine to 
replenish the thyroid’s iodine reservoir (29). 
D2 is considered the main T4-activating enzyme, given its high substrate affinity. D2 is 
a classical type-1 membrane protein, approximately of 31kDa, residing on the 
endoplasmic reticulum (ER) membrane, with a half-life of ~ 45 minutes (24). Its 
relatively short half-life is due to ubiquitination and proteasome uptake, a feature that is 
accelerated by D2 interaction with its natural substrate, T4 (30). D2 is expressed in 
many brain areas and is considered to play a major role in local T3 production in the 
brain. D2 is also expressed in pituitary, brown adipose tissue, placenta and in skeletal 
muscle (17). In contrast to D1, D2 is involved in outer-ring deiodination exclusively. 
The preferred substrate for D2 is T4 and, although to a lesser extent, rT3. D2 is 
regulated by thyroid hormones both pre- and post-transcriptionally as T3 downregulates 
D2 mRNA expression (31), while T4 as well as rT3 (the substrates of D2) increase D2 
ubiquitination and subsequently proteasomal degradation, resulting in decreased D2 
activity. D2 is required for normal mouse skeletal muscle differentiation of muscle stem 
cells (satellite cells) and regeneration (32). 
Deiodinase type 3 (D3) is viewed as the thyroid hormone inactivating enzyme, as it can 
only catalyze the inner-ring deiodination of T4 and T3. Like D1, D3 is present in the 
plasma membrane. The Dio3 gene is localized in the imprinted Dlk-Dio3 region of 
human chromosome 14 and mouse chromosome 12, and is expressed predominantly by 
the paternal allele. It is comprise a single exon, coding for a protein of 278 residues, 
with a molecular mass of about 32 kDa, including a selenocysteine-encoding TGA in 
the catalytic pocket and an SECIS element in the 3’UTR (33).  
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D3 is highly expressed in placenta and plays an important role during embryonic 
development protecting protect the fetus from excessive exposure to active thyroid 
hormone. D3 is also expressed in the brain and skin but in adult, healthy tissues 
expression levels are very low (17). Several studies have shown that D3 is expressed in 
activated leukocytes during bacterial and chemical inflammation	 (34) and that lacking 
D3 impairs bacterial clearance capacity during infection (35). D3 induction has also 
been shown during hypoxia in post-mortem liver biopsies of critically ill patients (36) 
and during myocardial infarction (37). Recent studies have revealed reactivation of D3 
expression in specific pathophysiological contexts correlated with hyperproliferation 
conditions as cancer. 
 
 
 
 
 
80% 
20 % 
Figure 2.3 Schematic of deiodinase-mediated thyroid hormone metabolism 
The thyroid gland produces principally (~ 80%) the biologically inactive precursor of TH, 
the thyroxine (T4). The TH action is initiated by the activation of T4 into T3, catalyzed by 
the type 2 iodothyronine deiodinase (D2). Both, T4 and T3 undergo inner ring 
deiodination, catalyzed by type 3 deiodinase (D3), generating inactive metabolites that do 
not interact with T3 receptors, reverse triiodothyronine (rT3) and 3,3’-diiodothyronine 
(T2), respectively. 
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2.3 Type 3 deiodinase and cancer 
Type 3 deiodinase, the main physiologic inactivator of TH, controls TH homeostasis by 
protecting tissues from an excess of TH. D3 is abundantly present in fetal tissues and in 
the human placenta, where it blocks the excessive maternal-to-fetal transfer to T4	(38). 
In contrast, during late neonatal and adult life, D3 expression is more limited and 
identified in only few postnatal tissues i.e. brain, skin and placenta	 (39). However, 
several studies have revealed the re-expression of D3 in different pathophysiological 
conditions, among which cardiac hypertrophy, chronic inflammation and ischemia	(17)	
(37). Moreover, this oncofetal protein results reactivated in the adult in highly-
proliferating and neoplastic cells. This finding suggests a link between deiodinase-
mediated TH metabolism and carcinogenesis. Indeed, D3-mediated local 
hypothyroidism promotes cellular proliferation by regulating the nuclear T3 availability. 
It has been reported that immortalized cell lines derived from different tumors such as 
basal-cell carcinoma (BCC), hemangiomas, hepatocarcinomas, breast cancer (MCF-7 
cells), colon adenocarcinoma (Caco2, SW280, and HCT116 cells), thyroid cancer, 
endometrium cancer (ECC-1 cells), and neuroblastoma (SH-SY5Y cells) express 
elevated D3 levels (40-42). D3 overexpression has been further verified in many human 
cancer tissues. Vascular tumors (hepatic hemangiomas) show high D3 activity resulting 
in an accelerated rate of THs degradation leading to a clinically relevant 
hypothyroidism named “consumptive hypothyroidism” (43,	 44). In benign adenomas 
and in colon carcinomas, D3 expression is significantly higher than in normal tissues 
but negatively correlated with the histologic grade of the lesions suggesting that D3 
could be a marker of the early stages of tumorigenesis. As already mentioned, an 
abnormal activation of Hedgehog pathway is implicated in the development of different 
types of cancer. There are several evidences that D3 is under the control of the Shh–Gli 
pathway. The activation of this pathway results in D3 overexpression in mouse and 
human BCC (45). By directly inducing D3 in keratinocytes, through Gli2, Shh causes a 
hypothyroid state at intracellular level resulting in increased cyclin D1 and higher 
proliferative rate. Shh-induced thyroid hormone degradation via D3 synergizes with the 
Shh-mediated reduction of the type 2 deiodinase, the thyroxine activating enzyme, and 
both effects are reversed by cAMP (45). Therefore, it has been shown that D3 
expression in BCC cells determines a proliferative advantage for the tumor and that, 
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conversely, D3 depletion interferes with tumorigenesis, enhancing the apoptotic 
process. By promoting Gli degradation, through protein kinase A induction, which in 
turn destabilizes Gli2 protein via its C-terminal degron, T3 blocks its transcriptional 
activity. Moreover, T3 treatment or D3 depletion reduce tumor growth in a genetically 
modified mouse model of skin tumorigenesis. By this mechanism, Shh induces TH 
signaling attenuation contributing to epidermal tumorigenesis in vivo by favoring cell 
proliferation and bypassing T3-induced growth arrest and cell differentiation. Also 
aberrant activation of the Wnt/β-catenin signaling pathway causes developmental 
defects and tumorigenesis. In particular, in colorectal cancers canonical Wnt signaling is 
aberrantly activated by mutations affecting either APC tumor suppressor gene (85%) or 
β-catenin-encoding CTNNb1 oncogene (10%). It has been recently shown that Wnt/ β-
catenin pathway directly affects TH signaling by a dual convergent mechanism, which 
modulates the activity of the deiodinase enzymes in colon cancer cells	 (42). 
Specifically, the TH activating D2 enzyme is down regulated by β-catenin while D3 is 
over-expressed by β-catenin/TCF complex. When D3 is absent, excess of T3 attenuates 
cell proliferation and promoted differentiation in both cultured cells and in xenograft 
mouse models. This is due to induction of E-cadherin, which sequestered β-catenin at 
the plasma membrane and promoted cell differentiation (42). Similarly to colon cancer, 
it should be postulated that deregulated Wnt pathway could induce D3 expression in 
other tumors.  
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2.4 MicroRNA and cancer : focus on miR-21 
MicroRNAs are an abundant subclass of non-coding RNAs of 18-25 nucleotides which 
act as endogenous regulators silencing gene expression through a process of post-
transcriptional modification. They exhibit varied and widespread functions during 
normal development and tissue homeostasis (46). MicroRNAs can be located in either 
introns and exons and are found in both coding and non-coding transcriptional units 
(47). Wherever their origin, they are transcribed by RNA polymerase II in the nucleus, 
generating “pri-miRNA,” a partially self-complementary oligonucleotide strand 
comprised of a core dsRNA stem-loop region flanked by two single-stranded tails. This 
precursor is subsequently cleaved by the RNase III enzyme (also called Drosha) into 
“pre-miRNAs,” a shorter (~70 nucleotides in length) hairpin-shaped dsRNA. This 
transient precursor exits the nucleus after interacting with Exportin-5, which facilitates 
its transport into the cytosol. Here, it is further processed by Dicer, an endoribonuclease 
which severs the loop from the stem, forming a mature (but still double stranded) 
miRNA duplex. To exert its effect, a mature miRNA depends on the assembly of 
ribonucleoprotein complexes, referred to as the RNA-Induced Silencing Complexes 
(RISCs). The RISC facilitates the dissociation of passenger and guide (targeting) 
strands, allowing the guide strand to inhibit translation by hybridizing to a target mRNA 
3’-UTR via partially complementary base pairing. The degree of complementarity 
appears to be an important predictor of the resulting fate of the mRNA target, as the 
RISC may instigate either degradation of the mRNA target (if match is highly 
complementary) or merely blockade translation (if the match is less highly 
complementary) (46).  
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Inspiringly, a recent study showed that a single miRNA may repress more than 100 
mRNAs on average and over 60% of human protein-coding genes are conserved targets 
of miRNAs	 (48). Given this vast majority of mRNA targets regulated by miRNAs, 
aberrant miRNA expression profoundly influences a wide variety of cell regulation 
pathways. Accordingly, miRNAs influence numerous cancer-relevant processes such as 
proliferation, cell cycle control, apoptosis, differentiation, migration and metabolism 
(49). In particular, during the past several years it has become clear that alterations in 
the expression of microRNA genes contribute to the pathogenesis of most, perhaps all, 
human malignancies. These alterations can be caused by a variety of mechanisms, 
including deletions, amplifications or mutations involving microRNA loci, by 
epigenetic silencing or by deregulations of transcription factors targeting specific 
microRNAs. In the context of cancer biology, miRNAs are often placed within a simple 
classification scheme as either an oncogenic miRNA (frequently abbreviated as 
Figure 2.4 Biogenesis and action of miRNAs  
miRNAs are transcribed in the nucleus by RNA polymerase II generating a primary miRNA 
(pri-miRNA) molecule, which is processed into a precursor miRNA (pre-miRNA) by the 
microprocessor complex comprised of Pasha and Drosha. Pre-miRNAs are exported to the 
cytoplasm by  Exportin 5 where are cleaved to create a microRNA duplex by Dicer enzyme. 
The duplex unwinds and the mature miRNA assembles into RISC. The miRNA base-pairs 
with target mRNA to direct gene silencing via mRNA cleavage or translation repression 
based on the level of complementarity between the miRNA and the mRNA target (Athina 
Markou 2016). 
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“oncomir”) or as a tumor suppressor miRNA. Deregulation of miRNAs can result in 
either increased or decreased expression depending on the scenario. In this way, both 
reduced and enhanced miRNA expression can promote tumorigenesis if the miRNAs 
subject to such events are tumor suppressors and oncomirs respectively. Among all 
cancer-related miRNAs, miR21 has been related to the pathogenesis of various 
malignant tumors, including glioblastoma, prostate, gastric, colon, breast and lung 
cancer (50-53). Its up-regulation has been shown to be self-sufficient in promoting 
proliferation and can evade apoptosis by targeting several tumor suppressors like PTEN 
and PDCD4	(54,	55). Furthermore, transgenic overexpression of miR21 results in B cell 
lymphoma demonstrating that miR21 is an “oncomiR”. In fact, when miR21 was 
inactivated, the tumors regressed completely in a few days. It has been shown that miR-
21 is transcriptionally activated by Stat3 (signal transducer and activator of transcription 
3) in the IL-6 signaling pathway (56). miR-21 exerts an anti-apoptotic function in k-
Ras-dependent lung tumors by inhibiting expression of Apaf-1, an important component 
of the intrinsic mitochondrial apoptotic pathway, and decreases protein levels of Fas 
ligand, a key initiator of the extrinsic apoptotic pathway. The function of miR-21 was 
further confirmed by the observation that ectopic expression of miR-21 protected cancer 
cells from gemcitabine-induced apoptosis. miR-21’s role is well characterized in 
invasion and metastasis. In fact, miR-21 promotes cell motility and invasion by directly 
targeting PTEN, a tumor suppressor known to inhibit cell invasion by blocking the 
expression of several MMPs (matrix metalloprotease) (57) (Fig. 2.5).  
Apart from being involved in cancerogenesis, miR21 plays a crucial role in a plethora 
of biological functions and diseases, namely development, cardiovascular diseases and 
inflammation (58)	miR21 is also expressed in skin, and its potential role as a regulator 
of skin homeostasis is demonstrated by its up-regulation in such diseases as psoriasis, 
atopic dermatitis, melanoma and squamous cell carcinoma (SCC) (59-61). However, 
nothing is known about miR21 expression in BCC. 
Among the few known targets of miR21 is grainyhead-like3 (GRHL3), a transcription 
factor expressed in the skin in the differentiated suprabasal layers and essential for 
epidermal differentiation and barrier formation at the end of mouse embryogenesis by 
regulating multiple genes important for executing the differentiation program in skin 
(62,	 64). These genes encode for structural proteins, lipid metabolizing enzymes and 
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cell-cell adhesion molecules. GRHL3 knock-out mice exhibit impaired epidermal 
differentiation and decreased expression of several genes involved in barrier formation 
(64). Furthermore, it was shown that epidermal-specific GRHL3 knockout mice exhibit 
thickened, hyperproliferative epidermis, as well as accelerated tumor formation and 
increased tumor ad carcinoma numbers than the wild-type controls. These mice show 
also increased Akt activation and reduced PTEN levels. Accordingly, in humans, 
dominant-negative GRHL3 mutations are associated with defective periderm 
development in Van der Woude syndrome (65). Moreover, GRHL3 was found to be a 
potent tumor suppressor in mouse and human SCC, and an upstream regulator of PTEN 
(62). In particular, it was identified a miR-21 proto-oncogenic network that 
simultaneously targets GRHL3 and PTEN leading to amplification of 
PI3K/AKT/mTOR signaling, cell hyperproliferation and induction of SCC (62). 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 miR21 targets 
miR21 can influence positively and negatively several biological processes, from 
block of apoptosis to promotion of cell proliferation, mobility and invasion though its 
effect on a number of targets (PDCD4, programmed cell death protein 4; PTEN, 
phosphatase and tensin homolog; MARKs, microtubule-affinity-regulating kinases; 
MMP, matrix metalloproteinase; Apaf-1, apoptotic protease activating factor-1) 
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2.5 Stem cells in skin cancer 
Skin is a complex tissue made of a structured combination of cell types. It has a 
remarkable regenerative capacity and contains several different kinds of stem cells 
(SCs). As in many adult tissues, also in the skin, stem cells (SCs) are responsible for 
tissue homeostasis and regeneration. Upon division, SCs can give rise to transit-
amplifying (TA) cell populations which, after several rounds of divisions, will 
terminally differentiate and eventually be lost from the tissue. In addition, adult SCs are 
activated following injuries, rapidly expand, and contribute actively to tissue repair 
(66). There is no unique marker of tissue-specific SCs, and SCs are usually defined by 
their functional properties, namely by their capacity for long-term self-renewal and their 
capacity to differentiate into one or multiple cell lineages (67). Epithelial skin stem cells 
(ESSCs) are thought to reside in a specialized area of the hair follicle called “the bulge”. 
Cells in this compartment possess the ability to differentiate, at least under stress 
conditions, into different cell lineages to regenerate not only the hair follicle but also the 
sebaceous gland (SG) and the epidermis. However, more recent studies presented 
compelling evidence for the existence of independent IFE (interfollicular epidermis) 
stem cells, as well as for isthmus stem cells, sebaceous gland (SG) stem cells and other 
epidermal progenitors (68,	 69). Lineage-tracing experiments reveal that during 
homeostasis, the different compartments of the epidermis are self-sustained by their 
own resident stem cells. Hair follicle bulge stem cells expressing the typical markers 
keratin 15 (K15), CD34 and Lgr5 (leucine-rich repeat-containing G-protein-coupled 
receptor 5) mediate hair follicle regeneration; Lgr6+ isthmus stem cells mediate 
turnover of the sebaceous gland cells and possibly of other epidermal lineages; and IFE 
stem and progenitor cells expressing keratin 14 (K14) sustain IFE homeostasis and 
maintenance of the skin barrier. Although under physiological conditions bulge stem 
cells do not contribute to the maintenance of the IFE, almost all stem cell populations of 
the epidermis, including the hair follicle bulge, Lgr6+ isthmus and IFE stem cells, can 
contribute to healing of the IFE after wounding (70-	73) (Fig. 2.6).  
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Unlike epidermal keratinocytes, which are committed to undergo terminal 
differentiation, skin stem cells have a long life span and this result in an ability to 
accumulate multiple genetic mutations that are necessary to induce cancer formation	
(74). When stem cells possess the ability to originate tumors they are called cancer stem 
cells (CSCs) (75). These tumor-initiating cells (TICs), are defined as a subpopulation of 
cancer cells with self-renewing capacity that possess high tumorigenic potential and can 
undergo multilineage differentiation to give rise to all types of cells present within the 
malignancies (76). In particular, different models have been proposed to explain tumor 
growth and heterogeneity. In the stochastic model of tumor growth, all cancer cells have 
the same intrinsic properties to contribute to tumors growth and choose between self-
renewal and differentiation in a stochastic manner (77,	78). In contrast, in the cancer 
stem cell (CSC) model, tumors are hierarchally organized, with only some tumor cells, 
called CSCs, presenting greater renewing potential that sustain long-term tumor growth 
Figure 2.6 Skin stem cells localization and markers 
The hair follicle structure is subdivided into distinct compartments. In each 
compartment exist basal cell populations that possess stem cell properties and are 
defined by distinct molecular markers. 
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(77,	 78). Many recent studies using prospective isolation of a fraction of tumor cells 
followed by their transplantation into immunodeficient mice have demonstrated that 
certain populations of tumor cells contain cells with higher probability to reform 
secondary tumor upon transplantation, supporting the existence of CSC	 (77,	 79). 
According to the CSC model, CSCs drive tumor growth and these cells are considered 
to be a cause of tumor relapse and disease progression, perhaps through their resistance 
to therapy and metastatic potential. Therefore, CSCs are currently extensively studied in 
various cancers.  
The field of CSC research truly started about 20 years ago when Dick and colleagues 
(80) published their pioneer studies demonstrating that only minor subpopulation of 
acute myeloid leukemia cells with CD34+/CD38− phenotype presents the potential to 
initiate leukemia in the immunodeficient mice	(80). Since then, large body of evidence 
has been published that supports the essential role of CSCs in initiation and progression 
of several hematological malignancies and of a wide range of solid tumors (81). In fact, 
many other groups have now demonstrated that in solid tumors only a fraction of cancer 
cells present the capacity to reform secondary tumors following their transplantation 
into immunodeficient mice (82). In particular, different solid tumors, including 
pancreatic cancer (83), squamous cell carcinomas (SCCs)	 (84), colon cancer (85), and 
melanoma (86), have been shown to contain subpopulations of tumor cells with greater 
ability to propagate the tumors in xenotransplantation assays.  
Recently, it was demonstrated that CD34-expressing tumor propagating cells (TPCs) 
with increased clonogenic potential and the ability to form secondary tumors upon 
transplantation into immune deficient mice have been isolated from DMBA/TPA-
induced skin SCC (87). However, it was later shown that both CD34HI and CD34LO 
tumor epithelial cell (TECs) populations from DMBA/TPA-induced skin SCC cultured 
in vitro 4 days before their transplantation present similar ability to reform secondary 
tumor upon transplantation into immune deficient mice (88). These two conflicting 
studies raise questions to whether CD34 expression can be used as marker to enrich for 
TPCs in skin SCCs. This matter was clarified using transplantation of limiting dilution 
of different populations of FACS-isolated tumour cells from four distinct mouse models 
of squamous skin tumours in order to investigate the frequency of tumour propagating 
cells (TPCs) at different stages of tumour progression. It was found that benign 
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papillomas, despite growing rapidly in vivo and being clonogenic in vitro, reformed 
secondary tumours upon transplantation at very low frequency and only when tumour 
cells were co-transplanted together with tumour-associated fibroblasts or endothelial 
cells. In two models of skin squamous cell carcinoma (SCC), TPCs increased with 
tumour invasiveness. Interestingly, the frequency of TPCs increased in CD34HI but not 
in CD34LO SCC cells with serial transplantations, while the two populations initially 
gave rise to secondary tumors with the same frequency (89). 
In this contest, several studies are coming out in order to establish the cells of origin 
from BCC and the possibility to use CD34 not only to isolate TPCs from SCC but also 
from BCC. However, in this regard no information are available yet, but the cellular 
origin of BCC has been debated for a long time. BCC was originally thought to derive 
from hair follicle stem cells due to its histological and biochemical similarities to hair 
follicles (90). However, recently studies demonstrated that BCCs can arise from the 
bulge, sebaceous glands, and IFE after Gli2 induction, and interestingly, different 
subtypes of BCCs (superficial versus nodular) developed depending on which 
compartments were being targeted for induction (91). Prior to this observation, recent 
studies using Cre-mediated cell-specific targeting both by lineage tracing and specific 
activation of Hh signaling in distinct skin cell populations gave unexpected results. 
Using clonal analysis of oncogene-targeted cells, Youssef and colleagues showed that 
more than 90% of SmoM2-induced BCCs arise from long-lived progenitors residing in 
the IFE, the rest arising from the upper infundibulum (92). Bulge SCs generate hyper-
plastic or dysplastic lesions upon SmoM2 expression, which do not progress into 
invasive cancer (92). Soon afterwards, Wang et al. presented conflicting data using 
lineage tracing (K15CrePR transgenic mice) in adult Ptch1+ /− mice to demonstrate that 
X-ray induced BCC arise exclusively from the follicular bulge, and that deletion of p53 
enhanced BCCs development from both the bulge and IFE in Ptch1+ /− mice (93). Taken 
together, these studies suggest that BCC primarily originate from hair follicle bulge 
stem cells but may be derived from other epidermal compartments under certain 
conditions (94).  
In a new study, using a genetic mouse model of BCC, some researchers report that 
Sox9, directly controls skin cancer formation by regulating the expansion of tumor 
initiating cells and the invasive properties of cancer cells. In fact, while Sox9 is not 
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expressed in the normal skin cells, Sox9 begins to be expressed in pre-cancerous lesions 
and is maintained in invasive tumors. Deletion of Sox9 prevents skin cancer formation 
demonstrating the essential role of Sox9 during tumorigenesis and leads to the 
progressive disappearance of the oncogene expressing cells. Moreover, Sox9 controls 
the long term maintenance and expansion of oncogene expressing cells by promoting 
self-renewing division and inhibiting differentiation. The authors uncover the cellular 
and molecular mechanisms, as well as the gene network regulated by Sox9 during the 
early steps of skin tumor initiation and demonstrate that Sox9 controls the long term 
maintenance and expansion of oncogene expressing cells by promoting self-renewing 
division and inhibiting differentiation. In addition, Sox9 acts also as key orchestrator of 
the extracellular matrix remodeling, cell adhesion and cytoskeleton dynamics required 
for tumor invasion. These results have important implications for the development of 
novel strategies to block tumor formation and invasion in the most frequent cancer in 
humans (95). Although considered as a stem cell marker, no studies so far have directly 
investigated its regulation by TH.  
It was recently introduced the concept that TH might modulate the behavior of CSCs. In 
particular, in the colon cancer stem cells TH influences stemness through its action on 
Wnt and BMP pathways. In fact, D2 and D3 are differentially expressed in different 
subpopulations of colon cancer stem cells according to their stem-like versus 
differentiated shape. Moreover, TH induces the differentiation of colon cancer stem 
cells and attenuates symmetric cancer cell division. In particular, D3 depletion increases 
the intracellular availability of TH that induced cell differentiation and sharply 
mitigated tumor formation. Furthermore, BMP4 is a direct thyroid hormone target and 
is involved in a positive feedback loop that modulates thyroid hormone signaling (115). 
However, few are the information about the influence of TH on skin cancer stem cells. 
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3 Aim of the project 
 
Thyroid Hormone (TH) is a pleotropic agent that has widespread biological functions 
such as control of cellular growth, development, tissue homeostasis and neoplastic 
transformation. At tissue level, TH action is regulated by the expression and activity of 
three selenodeiodinases, which catalyze TH activation (D1 and D2) and catabolism 
deiodinases (D3). The deoiodinase system is often altered in such pathological 
conditions as cancer. In fact, the type III deiodinase, that normally is absent in adult 
tissues, results re-activated in various types of human cancers where plays a critical role 
in the regulation of cell proliferation. Several studies have been demonstrated that D3 is 
overexpressed also in Basal Cell Carcinoma (BCC), the most frequent skin cancer (45). 
However, the precise role of TH in the BCC formation and maintenance is still 
unknown. Because SCs exist and proliferate for extended periods in adult tissue, they 
present, in theory, a higher chance of accumulating the necessary mutations to induce 
cancer formation (83). Based on above considerations, my PhD project aimed to 
understand how the local control of TH action can affect tumor growth in mouse 
models of BCC, which molecular mechanisms are involved in this regulation and 
how the intracellular concentration of TH can influence skin cancer stem cells 
maintenance. The functional interplay between TH and oncogenic pathways is likely to 
have broad implications, not only for the role of TH action in skin, but also for the 
identification of novel potential therapeutic strategies aimed at interfering with these 
signalings in other pathological contexts. 
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4 Results 
 
4.1 TH and microRNA: down-regulation of miR21 TH-dependent in BCC 
It was previously showed that TH regulates the proliferative potential of BCC cells in 
vitro and in vivo. In particular, It was demonstrate the existence of a cross talk between 
TH and Shh/Gli2, where Shh, through Gli2, directly induces D3 in mouse and human 
BCCs and, on the contrary, TH mediates Gli2 inactivation (45, 106). There were several 
reports indicating the involvement of miRNAs in many type of cancer. However, the 
regulation of these miRNAs has been poorly investigated and still remain largely 
unknown. TH is a pleotropic agent that has widespread biological functions 
nevertheless, no studies so far have directly investigated its functional role in regulation 
of microRNA. To explore whether TH action in BCC involves the regulation of 
miRNAs, we analyzed the differential expression of mature miRNAs (miChip) in D3-
silenced mouse BCC cells. We used a microarray platform of miRNA, the Exiqon 
platform, to compare the expression of miRNAs in BCC cells transfected with a control 
scrambled shRNA oligo versus the D3-targeting shRNA oligo. As showed by vulcano 
plot we found 46 miRNAs differentially expressed where the miR21 was the most 
sensitive target upon D3 depletion (Fig. 4.1 A). We validated miR21 as a negative TH 
target gene by measuring the mature miR21 transcript by TaqMan reverse transcriptase-
PCR (Fig. 4.1 B) and Northen blotting (Fig. 4.1 C and D) of BCC cells treated with 30 
nM T3 and in BCC cells transfected with D3-targeting shRNA, in which the TH signal 
was amplified (45). Moreover, the same analisys was conduced in BCC cells transfected 
with empy vector (CTR) or D3-overexpressing plasmid and in BCC cells grown in 
normal serum or in charcoal stripped serum for 48h (Fig. 4.1 E and F). Accordingly, 
while repressed by TH treatment and D3-depletion, miR21 was up-regulated by D3 
overexpression and by TH deprivation in serum.  
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Figure 4.1 Thyroid hormone reduce miR21 expression 
A. Genome-wide miRNA expression analysis in D3-depleted and control BCC 
cells. Selected deregulated miRNAs in shD3 relative to control cells are plotted 
against the p value; B. miR21 expression was measured by Taqman real time PCR 
in cDNAs from control BCC, shD3 and BCC cellstreated with 30 nM T3 for 
48hours; C-D. Northen blot of pre-miR21 expression in BCC cels treated with 
30nM T3 for the indicated days and in control BCC cells versus D3-depleted clones; 
quantification of miR21/5S ration; E-F. miR21 expression in BCC cells grown in 
normal serum or in charcoal stripped serum-containing medium for 48h. 
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4.2 miR21 is overexpressed in mouse BCC cells and tumors 
miR21 overexpression is an hallmark of tumorigenesis and mi21 has been found to be 
overactive in many tumors. In the skin, miR21 has been demonstrated to have 
oncogenic potential in squamus cell carcinomas (SCCs) and melanomas (61) but its 
relevance and expression in BCC has not been explored. Our studies indicate that TH 
influences miR21 expression in BCC cells. In order to explore the role of miR21 in 
BCC, we first validate the expression of miR21in BCCs. Therefore, we analyzed miR21 
expression by Taqman real time PCR in mouse BCC cells and tumors, from ear and tail 
regions, compared with normal skin and keratinocytes, respectively. We observed a 
robust over-expression of miR21 in both mouse BCC cells and tumors versus the 
normal counterparts (Fig. 4.2 A and B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 miR21 is highly expressed in mouse BCC 
A. miR21 was measured by Taqman real time PCR in mouse BCC tumors from ears 
and tails and the normal skin counterparts; B. miR21 was measured by Taqman real 
time PCR in BCC cells compared to keratinocytes. 
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4.3 TH regulates miR21 through it’s binding a specific gene region 
Given that TH down-regulates the miR21 expression we explore the possibility that TH 
directly inhibits miR21 transcription. To this aim, we analyzed the sequence of the 
miR21 enhancer region. In silico analysis revealed a conserved thyroid hormone 
responsive element-binding site (TRE) within the miR21 enhancer region (Fig. 4.3 A). 
We cloned 389 bp of the enhancer within the pGL3-basic vector to perform functional 
studies in the human embryonic kidney (HEK) 293 cell line and in mouse BCC cells. 
As shown in Figures 4.3 B and C, the miR21 enhancer was efficiently down-regulated 
by TH and by double TR-transfection-TH treatment in both cell lines, thus 
demonstrating that TH represses the transcription of the pre-miR21. To further 
demonstrate the interaction between the TH-TR and the TRE present into miR21 
enhancer regions, we performed a chromatin immunoprecipitation assay in BCC cells. 
As expected, chromatin immunoprecipitation analysis revealed that the thyroid receptor 
(TR) physically binds to the newly identified TRE (Fig. 4.3 D). Together, these results 
point to a negative regulation of T3 on the miR21 transcription via a direct T3-TR 
binding to the miR21 enhancer. 
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Figure 4.3 TH reduces miR21 by regulating miR21 enhancer region 
A. Organization of miR21 gene; B. HEK293 cells were transfected with miR21-Enhancer-
Luc plasmid +/- TRβ and treated with T3; C. BCC cells were transfected with miR21-
Enhancer-Luc plasmid +/- TRβ and treated with T3; D. ChIP analysis of the interaction 
between TRα and miR21 enhancer region. 
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4.4 miR21 positively regulates D3 expression 
Next, we asked whether miR21 is able to modulate TH signal in BCC cells. To this aim, 
we measured the expression of deiodinases D2 and D3 and other TH signaling 
modulators (TRα and ΤRβ, MCT8 and MCT10) in BCC cells transiently transfected 
with miR21. While mRNA of D2, thyroid hormone receptors and transporters were not 
modified by miR21 expression (Fig. 4.4 A), overexpression of miR21 strongly induced 
D3 levels in a time-dependent manner (Fig 4.4 A and B). In order to further investigate 
these findings, we inhibited miR21 in BCC cells by transfecting the LNA 
oligonucleotide complementary to miR-21 (LNA-antimiR-21) or with a control LNA 
oligonucleotide (LNA-scrambled, CTR). In accordance with its role as an inducer of D3 
expression, miR21 inhibition reduced D3 expression levels at mRNA and protein levels 
(Fig. 4.4 C). Importantly, the overexpression of miR21 also attenuated TH signal as 
demonstrated by the co-transfection of increasing amounts of miR21 along with an 
artificial T3-responsive promoter in BCC cells (Fig. 4.4 D). 
 
Figure 4.4 miR21 up-regulates D3 
A. BCC cell were transfected with miR21 and TH modulators were analyzed by real time 
PCR; B. real time PCR and western blot for D3 in BCC cells transfected with miR21; C. 
real time PCR and western blot for D3 in BCC cells transfected with anti-miR21; D. BCC 
cells were transfected with artificial T3-responsive promoter TRE3-TK and CMV-renilla as 
control. 
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4.5 GRHL3, a described  miR21 target, suppresses D3 expression 
miRNAs are well known to act inhibiting messenger RNA expression at post-
transcriptional level. Since D3 is induced by miR21, we tested the hypothesis that a 
direct miR21-target, and putative suppressor of D3, might mediate this effect. To this 
aim, we searched for miR21 downstream targets that could potentially inhibit D3 
expression. By using the computational algorithm Target Scan together with published 
and/or validated miR21 target genes, we obtained a list of genes potentially controlled 
by miR21. This list was further analyzed with the DAVID program for functional 
classification (96). By selecting the categories of “Regulation of transcription”, 
“Epidermal development” and “Tumor suppressor”, we found only a few genes that 
were present in all these three categories (Fig. 4.5 A). We tested the ability of three 
different genes belonging to these categories (TP63, KLF5 and GRHL3) to affect D3 
expression. We thus transfected ΔNp63α, KLF5 and GRHL3 in BCC cells and we 
analyzed D3 expression by western blot and real time PCR (Fig. 4.5 B and C). Among 
these, only one gene repressed D3 expression, namely GRHL3. In fact, GRHL3 
overexpression causes a D3 reduction in a time-dependent manner (Fig. 4.5 D).  
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Figure 4.5 miR21 up-regulates D3 by targeting GRHL3 
A. miR21 target genes were classified using DAVID program; B. real time PCR for D3 in 
BCC cells transfected with indicated plasmid; C. western blot for D3 in BCC cells 
transfected with indicated plasmid; D. BCC cells were transfected with Flag-GRHL3 
plasmid and D3 expression was measured by western blot. 
     Local control of thyroid hormone action in cancer growth and stemness      
  	
	 31	
GRHL3 is a transcription factor expressed in the skin in the differentiated suprabasal 
layers and essential for epidermal differentiation and barrier formation. Recently, it was 
demonstrated to work also as a tumor suppressor in mouse and human SCC (62, 64). 
We tested whether GRHL3 is a miR21 downstream target in the BCC cells, as already 
demonstrated in other cell contexts (62). To address this point, BCC cells transfected 
with miR21 or with anti-miR21 LNA were analyzed for GRHL3 mRNA and protein 
expression. We found that miR21 overexpression reduced GRHL3, while miR21 
silencing increased GRHL3 levels, thus validating GRHL3 as a miR21 target in the 
BCC cell context (Fig. 4.6 A and B). Importantly, the same effects were observed in 
primary cultures of keratinocytes in which, thanks to the very low level of endogenous 
miR21, overexpression of miR21 changed D3 and GRHL3 to a much greater extent 
than it did in BCC cells (Fig. 4.6 C). To determine whether GRHL3 negatively 
regulates D3 we knocked-down the endogenous protein using two different siRNA 
oligos (siGRHL3-1 and siGRHL3-2). As expected, D3 levels were significantly higher 
in BCC cells transfected with one or more siGRHL3 oligos, than in BCC cells 
transfected with scrambled oligos (siCTR). This result confirms that GRHL3 is a novel 
repressor of D3 expression (Fig. 4.6 D). 
 
Figure 4.6 miR21 up-regulates D3 by targeting GRHL3 
A. and B. GRHL3 mRNA and protein were measured in 
BCC cells transfected with miR21 or with anti-miR21; C. 
real time PCR for D3 and GRHL3 in keratinocytes 
transfected with miR21; D. BCC cells were transfected 
with two different siRNA GRHL3 and D3 protein was 
measured by western blot. 
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4.6 GRHL3 directly inhibits D3 expression 
All together our findings lead us to think that GRHL3 effectively is a D3 inhibitor. To 
this end, we tested whether GRHL3 directly binds to the Dio3 promoter. In silico 
analysis revealed a putative GRHL3 binding site within the promoter region of the Dio3 
gene (G1: GCGAACCGGAGCT), which is highly conserved, and located 436-bp from 
the ATG codon (Fig. 4.7 A). Functional studies demonstrated that GRHL3 binds to the 
G1 site and represses the activity of the Dio3 promoter. Indeed, co-transfection of the 
mouse Dio3 promoter (pmD3- Luc) with increasing amounts of GRHL3 showed that 
the Dio3 promoter is potently inhibited by GRHL3 (Fig. 4.7 C). To further demonstrate 
this regulation we mutagenize the G1 site within the Dio3 Promoter. As expected, 
mutation of the G1 site revealed that, while the basal activity of the mutated promoter 
was increased, the GRHL3-induced repression was abolished (Fig. 4.7 C and B). These 
data indicate that the tumor suppressor GRHL3 is a direct repressor of D3. 
 
Figure 4.7 GRHL3 is a direct D3 inhibitor 
A. Representation of G1 site responsive to GRHL3 within Dio3 locus; B. BCC cells were 
co-transfected with the wild type or mutant in the G1 site Dio3 promoter and were analyzed 
for luciferase activity; C. BCC cells were transfected with Dio3-Luc promoter or mut-Dio3-
Luc promoter and with increasing amounts of GRHL3 plasmid to analyzed the relative 
luciferase activity. 
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4.7 The miR21-GRHL3-D3 axis 
To assess the contribution of GRHL3 to the miR21-dependent D3 up-regulation, we 
transfected miR21 or GRHL3 or both in BCC cells. The forced expression of GRHL3 
down-regulated D3 expression and, most importantly, abolished the miR21-mediated 
induction of D3 (Fig. 4.8 A). This observation was confirmed by co-transfection of the 
Dio3 promoter with miR21 alone and with miR21 plus GRHL3. Also in this context, 
GRHL3 antagonized the effects induced by miR21 on D3 (Fig. 4.8 B). Interestingly, 
concomitant miR21 overexpression and GRHL3 down-regulation by siRNA did not 
result in synergistic D3 up-regulation, which reinforces the concept that suppression of 
GRHL3 is the mechanism by which miR21 enhances D3 (Fig. 4.8 C and D). Notably, 
miR21 and GRHL3 expression ultimately decreased and increased, respectively, the 
effect of TH in the nucleus (Fig. 4.8 E). The idea that emerges from these results is that 
miR21 up-regulates D3 expression by inhibiting the D3-repressor GRHL3. 
 
Figure 4.8 The miR21/GRHL3 axis regulates D3 expression 
A. D3 protein levels were measured by western blot from BCC cells transfected with miR21 and 
GRHL3 or both plasmids; B. BCC cells were co-transfected with the Dio3-Luc promoter and 
miR21, GRHL3 or both the extracts were analyzed for luciferase activity; C. BCC cells were 
transfected with miR21 and siRNA targeting GRHL3 and D3 expression was analyzed by 
western blot; D. BCC cells were co-transfected with Dio3-Luc promoter and miR21, siGRHL3 
or both and the luciferase activity was measured; E. the T3-responsive promoter TRE3-TK-Luc 
was co-transfected with miR21 or GRHL3 and luciferase activity was measured. 
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4.8 GRHL3 is positively regulated by TH 
Since TH negatively regulates miR21, we tested the possibility that TH treatment could 
in turn increase GRHL3 expression. BCC cells were treated with 30nM T3 for 1, 2, 3, 5 
days and GRHL3 expression was analyzed by western blot. We observed that T3 
treatment positively regulates GRHL3 in a time-dependent manner (Fig. 4.9 A). 
Moreover, to verify if this effect is mediated by miR21 we treated BCC cells with or 
without T3 and transfected with anti-miR21 or with LNA-control. The western blot 
analysis showed that treatment with T3 reduces the GRHL3 overexpression mediated 
by miR21 silencing (Fig. 4.9 B). Moreover, the immunofluorescence analysis of BCC 
cells treated with T3, and transfected or not with miR21, revealed that the increase of 
GRHL3 TH-dependent is mediated by miR21 (Fig. 4.9 C).  
 
Figure 4.9 GRHL3 is positively regulated by TH 
A. BCC cells were treated with 30nM T3 for the indicated times and protein were analyzed 
by western blot for GRHL3 expression; B. BCC cells were transfected with anti-miR21 and 
treated with or without T3 and protein were analyzed for GRHL3 expression; C. BCC cells 
were treated with 30nM T3 and transfected with miR21. The GRHL3 expression was 
analyzed by immunofluorescence. 
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4.9 Generation of D3KO cells using CRISPR/Cas9 technology and production of 
miR21 overexpressing cells 
To get insights into the mechanism by which miR21-D3 work we decided to use 
CRISPR/Cas9 technology to genetically deplete D3 in BCC cells (D3KO clones). We 
also stably overexpressed miR21 in BCC cells (miR cells). One representative D3KO 
clone was subsequently stably transfected with the miR21 plasmid, and, double D3KO-
miR21 overexpressing cells were selected (D3KO-miR cells). In this regards, we first 
confirmed D3 depletion in D3KO clones analyzing the generated clones by PRC, using 
the oligos shown in Fig. 4.10 A, and by western blot analysis for D3 (Fig. 4.10 B and 
C). In the same way, we analyzed the miR21 overexpressing clones by Taqman real 
time PCR for miR21 (Fig. 4.10 D). The D3 overexpression was verified in these clones 
by western blot analysis (Fig. 4.10 E). Finally, the double D3KO-miR21 overexpressing 
cells were analyzed by Taqman real time PCR and western blot analysis (Fig. 4.10 F 
and G). 
Because the level of miR21 was higher in BCC tissue than in normal skin, we tested 
whether the increase of miR21 exceeded its basal levels of transcription. Indeed, we 
observed that miR21 is 10-fold overexpressed in miR clones versus control BCC cells 
(Fig. 4.10 D). As shown, GRHL3 expression was very low in all generated cells, and 
was further suppressed by miR21 overexpression (Fig. 4.10 H and I). 
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Figure 4.10 Characterization of D3KO cells 
A. Representation of Dio3 locus and oligos used for PCR analysis; B. PCR analysis in 
clones generated using CRISPR/Cas9 technology; C. Western blot for D3 in clones 
generated using CRISPR/Cas9 technology; D. Taqman PCR analysis in miR21 
overexpressing clones; E. western blot for D3 in clones in miR21 overexpressing clones; F. 
Taqman PCR analysis in D3KO-miR21 overexpressing clones; G. western blot for D3 in 
clones in D3KO-miR21 overexpressing clones; H. and I. GRHL3 mRNA and protein in 
generated cells was measured by real time PCR and western blot. 
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4.10 BCC tumorigenesis required an intact miR21-GRHL3-D3 axis 
To assess the functional role of the newly identified network, we next subcutaneously 
injected the cells generated above into athymic (nude) mice and examined the weight 
and morphology of the resulting subcutaneous xenograft tumors. Tumors originating 
from miR cells grew rapidly, and were palpable 2 weeks after injection (Fig. 4.11 A and 
B). D3KO-miR cells generated much smaller tumors, which become palpable 3 weeks 
after injection, while D3KO cells did not generate tumors (Fig. 4.11 A-C). Importantly, 
miR21 overexpression exacerbated tumorigenesis versus control BCC cells (Fig. 4.11 
A-C). On the contrary, D3 ablation almost completely abolished the tumorigenic 
advantage acquired upon miR21 overexpression, consequently, D3 depletion results in a 
potent anti-tumoral effect even in the presence of an excess of mir21. Analyzing the 
formed xenograft we found a 3.54-fold reduction in tumor weight derived from D3KO-
miR cells and a 2.04 increase in tumor weight derived from miR21 cells, and a 4.2-fold 
reduction and a 2.2 increase in tumor volume derived from D3KO-miR and miR21 cells 
respectively, compared to control cell-generated tumors (Fig. 4.11 D and E). 
Accordingly, H&E staining, Ki-67 and Tunel staining showed that control and miR-
derived tumors have a high mitotic grade, while D3KO-miR-derived tumors showed 
multiple areas of cell death (Fig. 4.11 F and G).  
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Figure 4.11 D3 depletion reduces tumorigenic capacity of BCC in vivo 
A. 1*106/100 µl of control CRISPR-CTR cells (CTR), stable miR21 overexpressing (miR) 
BCC cells, CRISPR/Cas9-D3KO cells (D3KO) and double D3KO-miR cells were injected 
subcutaneously into the flanks of nude mice; B. Tumors were collected three weeks after 
injection; C. Tumor volume was measured with a caliper for three weeks in CTR, miR and 
D3KO-miR cells deriving tumors; D. and E. Tumor weight and volume measured three 
weeks after cell injection; F. and G. Tumor sections were analyzed by H&E staining and by 
immunofluorescence for Ki67 and Tunel expression in the indicated tumors. 
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4.11 Genetic D3 depletion reduces BCC-like tumor growth in vivo 
Having shown that D3 depletion drastically attenuates BCC tumorigenesis and miR21 
oncogenic potential in xenografts, we evaluated the role of D3 depletion in genetically-
induced BCC tumors in vivo. To this aim, we generated a keratinocyte-specific 
conditional D3 null mouse (K14Cre+/-/D3fl/fl) in a mouse model developing BCCs-like 
tumors (K5-Gli2)	 (15), thereby generating a spontaneously forming mouse BCC-like 
model in an epidermal-specific D3 null background, namely, K5Gli2/K14Cre+/-;D3fl/fl, 
henceforth referred to as “Gli2;D3KO”, while K5Gli2/K14Cre-/-/D3fl/fl mice (referred to 
as “Gli2”) served as controls (Fig. 4.12 A). Constitutive activation of Gli2 in 
keratinocytes of Gli2 mice resulted in epidermal hyperplasia, BCC and basaloid 
follicular hemartoma with conspicuous down-growth, arising mostly on the ears of mice 
at six months of age. Strikingly, D3 deletion in Gli2;D3KO mice reduced the number 
and size of tumors (Fig. 4.12 B). The few lesions that developed on the ears of 
Gli2;D3KO mice were much smaller than those found in Gli2 mice as shown by 
hematoxylin and eosin staining (Fig. 4.12 C).  
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Figure 4.12 D3 depletion reduces Gli2-briven BCC-like in vivo 
A. Genetic D3-depletion was specifically induced in keratinocytes by crossing 
K5Gli2;K14Cre-/+ with D3fl/fl mice; B. Mice were analyzed at 6 months of age when 
BCC-like formations were abundant and readily visible on the ears of control (Gli2) 
mice (n= 11); C. Histological analysis for hematoxylin and eosin stainings were 
performed on sections of ears from Gli2 and Gli2;D3KO mice. 
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To confirm that the BCC tumorigenesis was reduced in Gli2;D3KO mice compared to 
Gli2 mice we have analyzed by real time PCR and immunofluorescence the expression 
of  classic markers of BCC. Accordingly, the expression of K17, cyclinD1, Ptch1 and 
Sox9 was drastically reduced in D3-depleted mice (Fig. 4.13 A and B). Additionally, 
K10, a marker of the differentiating layers of the epidermis, was significantly down-
regulated in Gli2 mice, while it was well preserved in Gli2;D3KO mice (Fig. 4.13 B). 
 
Figure 4.13 in vivo D3 depletion reduces BCC markers 
A. Real time PCR for PTCH1, K17, Cyclin D1 and Sox9 in Gli2 vs Gli2;D3KO mice; 
B. Immunofluorescence staining for PTCH1, K17, K10 and D3 in Gli2 vs Gli2;D3KO 
mice. 
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4.12 The miR21-GRHL3-D3 axis is recapitulated in human BCC 
Lastly, we sought to address whether the regulation of T3 on miR21 and GRHL3 is 
recapitulated also in human BCC. To this aim, we evaluated miR21 levels in 16 human 
BCC tissues versus samples of healthy skin from the same patients by TaqMan real-
time RT-PCR. According to the concept that miR21 is a marker of tumorigenesis, 
miR21 was expressed at significantly higher levels in BCC tissue than in the healthy 
skin samples (Fig. 4.14 A). We also measured GRHL3 and D3 expression in the human 
samples by real time PCR. As expected, GRHL3 was highly expressed in normal skin 
and drastically repressed in most of the BCC samples (Fig. 4.14 B). On the contrary, D3 
expression correlated with miR21 expression being higher in BCC tumors compared to 
normal skin (Fig. 4.14 C). Taken together, these results confirm the model established 
in our study and suggest that targeting D3 and increasing the TH signal might represent 
a therapeutic approach to BCC. 
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Figure 4.14 miR21, GRHL3 and D3 correlation in human BCCs 
A. The expression of miR21 in 16 human BCC tumors compared with normal 
skin; B. The expression of GRHL3 was measured in 16 human BCC tumors 
compared with normal skin; C. The expression of D3 was measured in 16 
human BCC tumors compared with normal skin 
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4.13 TH and cancer stem cells: generation of conditional D3KO mice 
Hedgehog pathways deregulation leads to development of basal cell carcinoma, 
however the cell of origin for BCC is unclear. Several studies demonstrated that even in 
solid tumors only a fraction of cancer cells present the capacity to reform secondary 
tumors following their transplantation into immunodeficient mice. These cells, with 
increased renewal capacity and ability to recapitulate the heterogeneity founded in 
primary tumors, were referred to as cancer stem cells (CSCs) (78). Two critical 
properties contribute to the functional role of CSCs in the establishment and recurrence 
of cancerous tumors: their self-renewal capacity and their potential to differentiate into 
unlimited heterogeneous populations of cancer cells. These findings suggest that 
regulation of CSCs may represent an important mechanism to control the tumor 
progression. In this regard, we tested the possibility that TH metabolism affect the 
CSCs behavior. We thus generated two mouse model K14CRE-ER/Rosa-SmoM2-
YFP/D3fl/fl and K14CRE-ER/Ptch1fl/fl/D3fl/fl crossing K14CRE-ER/Rosa-SmoM2-YFP 
mice, that present a constitutive active SMO, and K14CRE-ER/Ptch1fl/fl, that have a 
conditional depletion of Ptch1, with D3fl/fl mice. In both mouse models D3 is 
specifically depleted in epidermis (Fig. 4.15 A and B). Furthermore, these models offer 
the possibility to have in the same cells the expression of SmoM2 or Ptch1 depletion 
and depletion of D3 contemporarily. Moreover, given that up to 70% of people with 
sporadic BCC have PTCH1 gene mutations and other 10-20% of patients presents 
mutations in the SMO these new mouse models better recapitulate the mutations in Hh 
pathway humans. 
 
 
 
 
     Local control of thyroid hormone action in cancer growth and stemness      
  	
	 45	
Figure 4.15 generation of D3KO conditional mice 
A. Genetic D3-depletion was specifically induced in keratinocytes by crossing K14CRE-
ER/Rosa-SmoM2-YFP with D3fl/fl mice; B. Genetic D3-depletion was specifically induced in 
keratinocytes by crossing K14CRE-ER/Ptch1fl/fl with D3fl/fl mice;  
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4.14 D3 is overexpressed in Smo- and Ptch1- dependent BCC 
To assess the biological relevance of TH on CSCs, we first confirmed D3 
overexpression in Smo- and Ptch1- dependent BCC tumors. In this regard, we analyzed 
the D3 expression in Smo- and Ptch1- dependent BCC tumors by western blot and real 
time PCR. As expected, D3 is overexpressed in both Smo- and Ptch1- dependent BCC 
tumors (Fig. 4.16 A and B). In particular, D3 is rapidly activated since 4 weeks of 
induction in K14CRE-ER/Rosa-SmoM2 mice and continued to be highly expressed at 8 
weeks, when BCC-like tumors were apparent, as shown by real time PCR and western 
blot analysis for D3 (Fig. 4.16 C). Interestingly, D3 co-localizes perfectly with Smo as 
shown by IF analysis (Fig. 4.16 D). Accordingly, together with an increase of D3 at 
mRNA level these mice present an overexpression of BCC markers such as K17 and 
Sox9 (Fig. 4.16 E). The same results were obtained using K14CRE-ER/Ptch1fl/fl mice. 
All together these data confirmed that D3 is overexpressed in Smo- and Ptch1-
dependent BCC and highlight D3 as a potential target for affecting BCC formation. 
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Figure 4.16 D3 expression in Smo- Ptch1- dependent BCC tumors: 
A. Immunofluorescence for D3 in K14CRE-ER/Rosa-SmoM2-YFP and K14CRE-ER/Ptch1fl/fl 
mice; B. Hematoxylin and eosin and Immunofluoresce staining in K14CRE-ER/Rosa-
SmoM2-YFP; C. Real time PCR and western blot analysis for D3 in K14CRE-ER/Rosa-
SmoM2-YFP 4 and 8 weeks after TAM administration; D. Co-staining for D3 and GFP in 
K14CRE-ER/Rosa-SmoM2-YFP; E. real time PCR for BCC markers. 
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4.15 TH metabolism affect skin cancer stem cells population 
Skin CSCs are a heterogeneous population of stem cells marked by a differential profile 
of high (Hi) versus low (Lo) CD34 expression, closely linked to the tumorigenic 
potential and capacity to reform the tumor in transplantation studies (89, 97). To define 
the impact of TH metabolism on CSC physiology we analyzed the percentage of CSCs 
in K14CRE-ER+/-/Rosa-SmoM2-YFP/D3fl/fl versus K14CRE-ER-/-/Rosa-SmoM2-
YFP/D3fl/fl mice by FACS analysis through co-expression of SmoM2 with YFP (yellow 
fluorescent protein) and analysis of CD34+ population cells. In this regard, 5 weeks old 
mice, K14CRE-ER+/-/Rosa-SmoM2-YFP/D3fl/fl versus K14CRE-ER-/-/Rosa-SmoM2-
YFP/D3fl/fl, were treated with tamoxifen to generate the concomitant D3 depletion and 
SmoM2-YFP overexpression. The mice were sacrificed 3 and 6 weeks after tamoxifen 
administration and CSCs were isolated from the tumor bulk using CD34 as marker of 
bulge CSCs. Interestingly, our data demonstrated that the number of CD34+ cells is 
reduced in D3-depleted epidermis as a result of the increased TH concentration and 
attenuated proliferative potential.  
Furthermore, in order to investigate the relevance of TH metabolism on CSCs, 
K14CRE-ER+/-/Rosa-SmoM2-YFP/D3fl/fl mice were made systemically hypothyroid by 
treatment with methimazole for 6 weeks and the CD34+ cells were analyzed by FACS 
analysis. Surprisingly, the treatment with methimazole prevents the reduction of CD34+ 
cells in K14CRE-ER+/-/Rosa-SmoM2-YFP/D3fl/fl mice (Fig.4.17).  
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Figure 4.17 D3 deplition reduces a population of CD34+ cells 
FACS strategy used to isolate YFP+/α6-integrin+ /CD34+ (Hi and Lo) cells from K14CRE-
ER+/-/Rosa-SmoM2-YFP/D3fl/fl versus K14CRE-ER-/-/Rosa-SmoM2-YFP/D3fl/fl mice. 
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4.16 Sox 9 is negatively regulated by TH 
In the last few years several studies have been demonstrated that Sox9, a bulge stem 
cells marker, normally involved in the control of cell fate decision during development 
and homeostasis of a broad range of tissues, is expressed in a wide range of cancers, 
including BCC. In particular, Sox9 is required for self-renewal of CSC in BCC tumor 
(95). However, Sox9 regulation is yet unclear. To get insights into the mechanism by 
witch TH could influence the population of CSCs we verify if TH signaling could 
influence Sox9 expression. To this aim, BCC cells were treated with 30nM T3 and were 
analyzed by western blot and real time PCR. Our data showed that Sox9 is down-
regulated by T3 treatments (Fig.4.18 A and B). Furthermore, D3-depletion in BCC 
cells, using D3-targeting shRNA oligo versus control scrambled shRNA oligo, also 
causes a reduction of Sox9 mRNA (Fig. 4.18 C). 
 
Figure 4.18 Sox9 is downregulated by TH in BCC cells 
A. Real time PCR and western blot analysis for Sox9 in BCC cells treated with 30nM T3 for 
48h; B. western blot analysis for Sox9 in BCC cells treated with 30nM T3 for 48h; C. Real 
time PCR for Sox9 in BCC cells transfected with shD3. 
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4.17 TH regulates SOX9 through it’s binding a specific gene region 
To further investigate the mechanism by which TH inhibits Sox9 expression, we 
analyzed the Sox9 regulatory region. In silico analysis revealed several conserved 
thyroid hormone responsive element-binding sites (TREs) within the mouse Sox9 5’-
Flanking regions (Fig. 4.19 A). We cloned 1241 bp of the 5’-Flanking region within the 
pGL3-basic vector to perform functional studies in mouse BCC cells. As shown in Fig. 
4.19 B, the Sox9 enhancer was efficiently down-regulated by TH and by double TR-
transfection-TH treatment in BCC. Finally, to further support these findings, we 
performed chromatin immunoprecipitation analysis. The results revealed that the 
thyroid receptor (TR) physically binds to the one of the most conserved TREs (Fig. 4.19 
C). Together, these results demonstrate that TH represses the transcription of the 
stemness gene Sox9. 
 
Figure 4.19 TH binds Sox9 5’-Flanking region in BCC cells 
A. Representation of Sox9 5’-Flanking Regions; B. BCC cells transfected with Sox9-Luc 
promoter and lucefesase activity was measured; C. Chromatin immunoprecipitation analysis 
revealed that the thyroid receptor (TR) physically binds to the one of the most conserved 
TREs in Sox9 5’-Flanking Regions. 
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5 Discussion 
 
The thyroid hormone (T3) acts on different signaling pathways to control intrinsic 
transcription factor networks regulating the balance between proliferation versus 
differentiation in several contexts. Additionally, current literature suggests that TH have 
an important role in neoplastic transformation. Our studies have identified a novel 
network through TH signaling, by modulating miRNA expression, interacts with 
oncogenic pathways to regulate the growth of BCC tumors. Specifically, we provided 
evidence that T3 suppresses miR21 expression, thus attenuating BCC formation. 
Moreover, TH action is contextually regulated by miR21 through the control of the TH-
inactivating enzyme, D3. Of note, thyroid hormone deregulation is frequent in human 
tumors, but it is unknown whether it is a bystander event or if it could drive or control 
in vivo cancer growth. Presently, not much evidence exist in literature regarding the 
cross-talk between TH signaling and microRNA in cancer. Notably, several evidences 
have indicated that the TH-inactivating enzyme D3 is up-regulated in many human 
tumors and cancer cell lines (38) where, blocking TH action, enhances the proliferation 
of malignant cells (45). Here we described a TH functional role in the control of miR21-
dependent oncogenic action. Importantly, using a unique skin-specific D3-KO mouse 
model, we provided the first in vivo genetic evidence that D3 depletion, which is 
equivalent to TH treatment, drastically reduces BCC formation. In particular, the 
primary TH mode action is its binding to TH receptors in the nucleus, which are able to 
binding to TH response elements (TREs) and impose a gene expression signature that 
activates or inhibits target genes transcription. However, a direct TR-TRE mechanism 
may not explain all TH actions. Therefore, miRNAs represent an additional mechanism 
by which TH could regulate target genes. miRNAs are involved in many biological 
processes and functions, which control protein expression principally through mRNA 
degradation (47). Moreover, studies in the past 10 years have evidenced that alteration 
in microRNA expression and regulation contributes to the pathogenesis of most 
malignancies (51-55). Similarly, TH signaling is often compromised in carcinogenesis 
as demonstrated by the reduced expression or deletion of the TR genes in human 
cancers, suggesting that TRs could function as tumor suppressors. The inverse 
association between TH and cancer was confirmed by the demonstration that the v-erb-a 
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oncogene, which is the avian erythroblastosis gene, is a mutated form of the Thra gene 
(coding for the TRa protein) (98). It antagonizes T3 function AEV-transformed 
erythroleukemic in cells thus blocking T3-dependent cell differentiation. Therefore, 
both T3/thyroid hormone receptor signaling and miRNAs affect tumor cell progression. 
As such, in the current work we explored the miRNAs’ role in governing TH action in 
BCC context. In this light, it is of critical relevance the novel finding of a negative 
control exerted by T3 on miR21 expression. Established as “onco-miR” miR21 was 
demonstrated acts in a plethora of cancer (57, 99,	 100). In skin, miR21 has been 
implicated in tumorigenesis of SCC and melanomas (62,	 101), but also in psoriasis 
(102) and wound healing (103). Here, we provide the first evidence that miR21 is 
overexpressed in human and mouse BCC, while it is barely detectable in normal skin. 
Our data demonstrate that miR21 is suppressed by TH at transcriptional level by 
directly binding to a TRE located within the miR21 enhancer region. Indeed, decreased 
expression of D3 or TH treatment of BCC cells contributes to miR21down-regulation 
levels. Furthermore, we described the existence of a loop between T3 and miR21 due to 
the fact that miR21 is also an upstream regulator of D3, the T3-inactivating enzyme. It 
is been known that miRNAs reduce gene expression by targeting the 3-UTR regions of 
downstream mRNAs and blocking their translation. The positive correlation between 
miR21 and D3 suggests the existence of an intermediate factor that mediates such 
regulation. To accomplish this, we have screened a downstream target of miR21, 
trascriptor factors express in the epithelium, as a putative suppressor of D3 expression. 
Consequently, we discovered a novel D3 repressor, grainyhead-like 3 (GRHL3). Our 
data demonstrate that the developmental factor and tumor suppressor GRHL3 represses 
D3 transcription and mediates the positive regulation of D3 expression by miR21. 
Consistent with the computational analysis, some studies have demonstrated that 
GRHL3 is down-regulated by miR21 in SCCs	 (62,	 (64). Accordingly, here we 
demonstrated that GRHL3 is down-regulated by miR21 in BCC and this inhibition 
increases the D3 expression. This is consistent with the poor D3 expression in adult 
tissues and its reactivation in many tumor contexts (38). Remarkably, forced GRHL3 
expression prevents miR21-dependent D3 transcription, thus providing a genetic proof 
for a miR21-GRHL3-D3 network (Fig. 5.1).  
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Our findings suggest that TH metabolism has a critical role in the skin. Consistent with 
these results, both miR21 and GRHL3 play crucial roles in skin cancer formation (64). 
Particularly, keratynocytes derived from GRHL3-/- mice displaied increased 
tumorigenesis when injected in nude mice, demonstrating a tumor suppressor role in 
skin cancer. Accordingly, previous reports have shown the oncogenic activity of miR-
21 including high proliferation, low apoptosis, and high invasion and metastasis 
potential. Moreover, Hatley et al. (2010) revealed, for the first time, a miR-21 
oncogenic potential in vivo by using gain-of-function transgenic mice and loss-of-
function knockout mice of miR-21 allele in combination with the K-rasLA2 mouse model 
of NSCLC (CAG-miR-21; K-rasLA2 and the miR-21−/−; K-rasLA2, respectively). Indeed, 
miR21 inhibition in miR-21−/−; K-rasLA2 mice drastically attenuates tumor growth. 
These observations reinforce the idea that D3 expression, and in general TH 
metabolism, play a critical role in skin cancer. Furthermore, it was previously 
demonstrated that D3 overexpression enhances keratinocyte proliferation (45), and that 
Figure 5.1 miR21-GRHL3-D3 axis 
Schematic representation of miR21-GRHL3-D3 axis through BCC cells regulates 
intracellular T3 availability 
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D3 is normally absent in adult tissues while is re-activated in many hyper-proliferative 
conditions (38). The inverse correlation between miR21 and GRHL3, and consequently 
of D3 and GRHL3, shown by our studies, underline the opposite roles played by the 
two genes in BCC tumorigenesis. In addition, miR21 and GRHL3 are also related to 
others pathologies of skin in which the proliferation control is enhanced, such as 
psoriasis and wound healing (104) thus suggesting that D3-mediated control of T3 
signaling might also be active in these conditions. Finally, given that GRHL3 is a 
critical factor for keratinocyte differentiation and skin barrier formation and that Grhl3-/- 
mice exhibit impaired epidermal differentiation and decreased expression of multiple 
differentiation genes	 (105), we can suppose that D3 suppression and TH regulation 
could influence the differentiation program of keratinocytes. Such a speculation might 
have important clinical relevance, since alterations of thyroid hormone levels in patients 
are associated with cutaneous manifestations and generalized myxedema (increased 
glycosaminoglycan deposition in skin, which appears cold, dry and pale, with abundant 
hair loss) is the classical clinical sign of hypothyroid patients (106). Although thyroid 
dysfunctions affect the skin phenotype and many people with hypothyroidism and 
hyperthyroidism have skin-related conditions (106), there is no evidence of an 
association between thyroid dysfunctions and BCC formation. This apparent lack of an 
association may be explained in one of two ways. Firstly, BCCs grow very slowly while 
alterations of thyroid hormone circulation at plasma levels are acute conditions that 
generally do not become chronic. Secondly, the deiodinase family represents a potent 
homeostatic mechanism when thyroid dysfunction induces a minimal variation of TH, 
and is thus able to preserve intracellular “normal” T3 concentrations even in the 
presence of altered thyroid status at plasma level.  
Taken note of these considerations, we sought to assess the pathologic role of the newly 
identified circuit in vivo. For this purpose, we used a CRISPR/Cas9 technology to 
genetically deplete D3 in BCC cells. Additionally, we create a miR21-overexpressing 
BCC cells and D3ko- miR21-overexpressing BCC cells. Our results demonstrated that 
D3 depletion potently attenuates BCC cell proliferation in vivo xenograft. On the 
contrary, miR21 overexpression enhances the oncogenic potential of BCC cells. Most 
remarkably, the ability to form tumors of miR21-overexpressing cells was significantly 
compromised by D3 depletion, which strongly supports the concept that the TH 
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inactivation pathway plays a pivotal role in tumor growth. Furthermore, the intracellular 
TH regulation by D3 seems to be critical for tumorigenic potential in an in vivo model 
of BCC-like tumor formation. Indeed, we demonstrate that skin-specific D3 depletion 
drastically reduces tumor occurrence in mice with spontaneously-forming BCC tumors, 
and prevents miR21 overexpression in these tumors. Interestingly, our data demonstrate 
that it is possible attenuates skin cancer formation by blocking the down-regulation of 
TH signaling. However, even if D3 depletion potently attenuates BCC growth driven by 
the Shh-Gli2 pathway and by miR21 overexpression, BCC cells still generate tumors 
when miR21 is overexpressed and D3 is depleted, thus suggesting that increasing the 
intracellular thyroid hormone signaling is not sufficient to eradicate BCC 
tumorigenesis. Collectively, these findings suggest that TH may regulate the cellular 
levels of miRNA which, in turn, regulate the TH intracellular availability. To our 
knowledge, this represents the first observation of strong link between miR21 
expression and D3 overexpression. Besides in cancer, there are many other contexts in 
which miR21 functions, D3 expression and TH metabolism are linked. For instance, 
miR21 is implicated in many types of cardiac stress, including the myocardial 
remodeling that occur after infarction, in which both D3 and miR21 are induced (107). 
Moreover, miR21 is induced during immune cell activation (58, 108). The analogy of 
miR21 with D3 expression in multiple settings suggests that the miR21-D3 axis is a 
potential therapeutic target. In conclusion, the first part of this work leads us to 
conclude that exist a common route by which tumor cells attenuate the TH signal in the 
tumor microenvironment (Fig. 5.2).  
 
 
 
 
 
 
 
 
Figure 5.2 TH-miR21 loop 
Schematic representation of the mutual, negative-feedback loop by which TH regulates 
miR21 and miR21 controls intracellular TH through GRHL3. 
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In the second part of this study, we provide the first evidence that TH controls the skin 
cancer stem cells maintenance. Here we demonstrated that TH act not only down-
regulating and important stemness gene, Sox9, but also reducing the proportion of 
CD34+ in the bulk of tumor. Sox9 exhibits several functions in embryogenesis, sex 
determination as well as maintenance of stemness properties (109).	Apart from their 
physiological functions, numerous studies have also highlighted the important 
involvements of Sox9 in tumorigenesis of a number of human malignancies such as 
colorectal, pancreatic, prostate cancers and skin	(110,	111). In the normal skin, Sox9 is 
expressed in the sebaceous gland and in the bulge (112). In epidermal keratinocytes 
Sox9 plays an important role in proliferation, differentiation and apoptosis processes 
(113). Several studies have been demonstrated that Sox9 depletion in early stem cells 
can block hair follicle morphogenesis and epidermal wound repair	(112). In this regard, 
the role of Sox9 as a cell fate determiner during embryonic development has been well 
characterized. In particular, Sox9 expression is related to differentiation of cells derived 
from all three germ layers into a several specialized tissues. However, Sox9 is express 
not only in pluripotent progenitors but also in adult stem cells, suggesting its role in cell 
maintenance and specification during adult life. During last few years, several studies 
have characterized the versatile role of Sox9 as a stem cell regulator. Indeed, recent data 
have demonstrated that Sox9 controls the long-term maintenance and expansion of 
oncogene expressing cells by promoting self-renewing division and inhibiting 
differentiation (114). This versatility of Sox9 may be explained by a combination of 
pre- and post-transcriptional regulations. Accordingly, it was demonstrated that TH 
regulates the self-renewal of colon cancer stem cells through the activation of canonical 
Notch pathway (115). Other studies provide the evidence that TH promotes cell self-
renewal and drugs resistance also in HCC cells (116). 
Here we described the ability of T3 to regulate Sox9 expression. In particular, our data 
suggest that Sox9 is down-regulated by T3 treatment and specifically the thyroid 
receptor physically binds the TRE within Sox9 5’-Flanking Regions. Most remarkably, 
D3-depletion in BCC cells also causes a reduction of Sox9 levels. These data lead us to 
hypothesize that TH may have a yet uncharacterized functional role in the regulation of 
skin stemness genes. In line with this idea, we have analyzed the role of TH on BCC-
CSCs. Several studies have demonstrated that BCCs can arise from CSC of bulge, 
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sebaceous glands, and IFE (91, 92,	 94). The cell surface glycoprotein CD34 marks 
mouse hair follicle bulge cells (117)	 that are thought to be major target of carcinogens 
and the cells of origin for skin tumors in mice and humans (118). Because of that, we 
have generated two mouse model (K14CRE-ER/Rosa-SmoM2-YFP/D3fl/fl and 
K14CRE-ER/Ptch1fl/fl/D3fl/fl), in which D3 is specifically depleted in epidermis 
simultaneously with the Smo overexpression or Ptch1 depletion. We demonstrated that 
skin specific D3-deplition, leading to increased TH action, causes a reduction of CD34+ 
cells in BCC. Most importantly, systemically hypothyroidism of these mice prevents the 
percentage diminution of CD34+ population. 
We thus speculate that TH signaling is essential for the maintenance of bulge CSC.  
Although these findings provide the first evidence that the absence of D3 dramatically 
impairs CSC population, yet a key question remains open: which is the mechanism 
trough TH signaling can act in modulating cancer stem cells.  
In conclusion, our findings identify the TH-inactivating enzyme D3 as a potential target 
of anti-cancer therapy for human BCC and demonstrate that TH functions as a 
suppressor of BCC tumors by regulating multiple pathways, including regulation of 
CSCs. 
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6 Materials and Methods 
 
6.1 Cell cultures and transfections 
BCC cells were cultured under low calcium conditions with 8% Ca2+-chelated fetal 
bovine serum and keratinocyte growth factor (Sigma). HEK-293 cells were cultured in 
DMEM with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 10 U/mL 
penicillin/streptomycin. All transient transfections for BCC cells were performed using 
Lipofectamine 2000 (Life Technologies, Ltd) according to the manufacturer’s 
instructions. HEK-293 cells were transfected using IBAfect reagent (IBA 
BioTAGnology). Mouse primary keratinocytes were isolated from C57BL/6 newborn 
mice and cultured under low calcium conditions (0.05 mM) in the presence of 4% 
calcium-chelated fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA) and 
epidermal growth factor (EGF, Invitrogen). 
 
6.2 Plasmid and reagents 
For the pmD3Luc (Dio3 Promoter) a genomic mouse DNA was used as a PCR 
template; the oligonucleotides pmD3U and pmD3L (see paragraph 6.15) generated a 
750-bp fragment containing the mouse dio3 5' flanking region. For the miR21-
Enhancer-Luc plasmid, we used the oligos mMiR21U and mMiR21L to amplify 389 bp 
of the miR21 5' flanking region. The amplified regions were cloned into the NheI/BglII 
(pmD3Luc) or SacI/XhoI (miR21-Enhancer-Luc) sites of a pGL3-basic vector 
(Promega). The mutated plasmid pmD3Luc-del was obtained from the pmD3Luc by 
recombinant PCR with two sets of oligonucleotides. Briefly, the two PCR 
products,pmD3U/pmD3mGRHLL2 and pmD3mGRHLU/pmD3L to obtain pmD3Luc-
del were combined by PCR using outside oligonucleotides, and the final PCR products 
were reinserted into the pGL3-basic vector (Promega). The Flag-GRHL3 plasmid was 
generated by PCR on mouse normal skin cDNA; the coding sequence of mouse grhl3 
was amplified by PCR with specific oligonucleotides (mGRHL3clonU and 
mGRHL3clonL); the PCR product was inserted into the HindIII/EcoRI sites of the 
pFLAG-CMV-2 vector (Sigma). To generate the pmSox9Luc plasmid, we used a 
genomic mouse DNA as template in a PCR with oligonucleotides: pmSox9U and 
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pmSox9L2 to isolate 1241 bp from the mouse Sox9 5' flanking region. The amplified 
region were cloned into Xho/HindIII sites of a pGL3-basic vector (Promega). 
GRHL3 silencing was performed with siRNA technology: two siRNA targeting GRHL3 
were purchased from Life Technology (cod. s106644, s106646). Stealth RNAi negative 
control duplex (Invitrogen) served as control. The primer sequence is reported at 
paragraph 6.15. The miR21-overexpressing plasmid was kindly provided by Prof. G. De 
Vita (University of Naples Federico II,Naples, Italy). Knockdown of miR-21 was 
performed by transient transfection of anti-miR21 LNA (ID mh10206, Ambion). LNA-
scrambled CTR served as control. 
 
6.3 Genome-editing of the dio3locus using the CRISPR/Cas9 technology 
Targeted depletion of D3 in mouse BCC cells was obtained with CRISPR/Cas9 
technology by using the CRISPR/Cas9 system from Santa Cruz Biotechnology (dio3 
CRISPR/Cas9 KO Plasmid, Cod. sc-430733) and control plasmid (Control 
CRISPR/Cas9 Plasmid, cod. sc-418922). The D3 CRISPR/Cas9 KO plasmid consists of 
a pool of 3 plasmids, each encoding the Cas9 nuclease and a target-specific 20 
nucleotide guide RNA. CRISPR/Cas9-guided mutagenesis in this case resulted in a 
deletion in the dio3 coding region. Briefly, BCC cells were transfected with 500 ng of 
the D3 CRISPR/Cas9 KO plasmid or control plasmid with Lipofectamine 2000 (Life 
Technology). Three days after transfection, the cells were FACS-sorted for green 
fluorescent protein expression, and single clones were selected and analyzed by PCR to 
verify D3 coding sequence integrity using specific oligonucleotides (gdio3U: 
cgacccaagatttctggggca and gdio3L: agcagagtctcaagttagccagac). Effective D3 depletion 
was confirmed by western blot analysis. 
 
6.4 Luciferase assay 
The Luc plasmids (pmD3Luc,miR21-Enhancer-Luc or T3TRETKLc, pmSox9Luc) and 
CMV-Renilla reporters were co-transfected into BCC and HEK-293 cells, andtreated 
with 30 nMT3 as indicated. Luciferase activities were measured 48 hours after 
transfection by using the Dual Luciferase Reporter Assay System (Promega), and 
differences in transfection efficiency were corrected relative to the level of Renilla 
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activity. Each construct was studied in triplicate in at least 3 separate transfection 
experiments. 
 
6.5 Western blot analysis 
Total protein extracts from BCC cells were run on a 10% SDS–PAGE gel and 
transferred on Immobilon-P transfer membrane (Millipore). The membrane was then 
blocked with 5% non-fat dry milk in phosphate buffered saline (PBS), probed with 
appropriate antibodies (anti-D3 polyclonal antibodies (1:500); anti-Flag M2-Sigma 
(1:1000); cyclin D1 (1:1000) Santa Cruz, sc-246) for 2 h, washed and incubated with 
horseradish peroxidase-conjugated donkey anti-rabbit IgG or anti-mouse secondary 
antibody (1:3000) and detected by chemiluminescence (Millipore). After extensive 
washing, the membrane was incubated with anti-Tubulin-specific antibodies (sc -8035, 
1:10000; Santa Cruz) as loading control. All Western blots were run in triplicate, and 
bands were quantitated in one representative gel. 
 
6.6 miRNA Northen blot 
Total RNA was isolated from BCC cells treated or not with T3, using Trizol 
(Invitrogen) and quantitated at 260 nm using a standard spectrometry. 10 μg of total 
RNA was resuspended in 2 X tris/borate/EDTA (TBE) urea sample buffer (Invitrogen) 
to a final volume of 10 µl. Samples were heated at 70 °C for 5 min and loaded onto a 
15% polyacrylamide gel containing TBEurea. Electrophoresis was performed in 1 X 
TBE running buffer at 120 V with a run time between 60–90 min. After electrophoresis, 
the gel was rinsed in deionised water, followed by a 5 min wash in 1 X TBE. RNA was 
transferred onto a Hybond N+ membrane for 30 min at 20 V using a 
BioRadMiniprotean II apparatus. The nylon membrane was placed in the Stratagene UV 
Cross linker® and RNA cross-linked at 1200 kJ. As miR21 probe, we designed the 
oligonucleotide Mir21probe (see paragraph 6.15) containing the mature miRNA 
sequence. The oligo was hybridized to the OprobAAA: 5’ TTTTTTTTTTCTCTGTCC-
3’ and elongated with klenowexo- and ATPalpha P32 to generate a tail of radioactive 
adenine. To normalize the RNA, we used the 5s subunit of ribosomal RNA (see 
Supplemental Table 3), which was also hybridized to the OprobAAA and radiolabeled. 
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6.7 Animals, histology and immunostaining 
.K5Gli2;K14Cre+/-D3fl/fl(Gli2;D3KO) mice were obtained by crossing a keratinocyte-
specific conditional D3 null mouse (K14Cre+/-D3fl/fl) with the mouse model K5-
Gli2(119). Female 5-week-old BALB/C (nude) mice were purchased from Charles 
River Laboratories (Milan, Italy). K14CRE-ER/Rosa-SmoM2-YFP/D3fl/fl mice were 
obtained by crossing K14CRE-ER/Rosa-SmoM2-YFP mice with D3fl/fl mice. K14CRE-
ER/Ptch1fl/fl/D3fl/fl were obtained by crossing K14CRE-ER/Ptch1fl/fl with D3fl/fl mice. 
For immunofluorescence and histology, ears from Gli2;D3KO and control mice at 6 
months of age and xenograft tumors were and embedded in paraffin, cut, into 7 µm 
sections, and hematoxylin and eosin stained.Slides were baked at 60 °C, deparaffinized 
by xylenes, dehydrated with ethanol, rehydrated in PBS, and permeabilized by 0.5% 
Triton X-100 in PBS. Antigen retrieval was performed by incubation in 0.01 M citrate 
buffer (pH 6.0) or 0.5 M Tris buffer (pH 8.0) at 95 °C for 15 minutes. Sections were 
blocked in 1% BSA/0.05% Tween/PBS for 30 min at 37 °C. Primary antibody (Anti-
K17 (Novocastra, NCL-CK17), K10 (PRB-159P), Sox9 (AbCam, ab26414) and Ptch-1 
(Novus Bio 2113) GFP (AbCam, ab13970)) incubation was carried out overnight at 
4 °C in blocking buffer followed by washing in 0.2% Tween-PBS. Secondary antibody 
incubation was carried out at room temperature for 1 hour, followed by washing in 
0.2% Tween-PBS. Images were acquired with an IX51 Olympus microscope and the 
Cell*F software.  
 
6.8 Real time PCR 
mRNAs were extracted with TRIzol reagent (Life Technologies Ltd). cDNAs were 
prepared with SuperScript VILO Master Mix (Life Technologies Ltd) as indicated by 
the manufacturer. The cDNAs were amplified by PCR in an iQ5 Multicolor Real-Time 
Detector System (Bio-Rad) with the fluorescent double-stranded DNA-binding dye 
SYBR Green (Applied Biosystems). Specific primers for each gene were designed to 
work under the same cycling conditions (95°C for 10 min followed by 40 cycles at 
95°C for 15 s and 60°C for 1 min), generating products of comparable sizes (~200 bp 
for each amplification). Primer combinations were positioned whenever possible to 
span an exon-exon junction and the RNA digested with deoxyribonuclease to avoid 
genomic DNA interference. For each reaction, standard curves for reference genes were 
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constructed based on 6 4-fold serial dilutions of cDNA. All samples were run in 
triplicate. The template concentration was calculated from the cycle number when the 
amount of PCR product passed a threshold established in the exponential phase of the 
PCR. The relative amounts of gene expression were calculated with cyclophilin A 
expression as an internal standard (calibrator). The results, expressed as n-fold 
differences in target gene expression, were determined as follows: n × target = 2(ΔCtsample 
- ΔCtcalibrator). 
 
6.9 TaqMan miRNA assay 
miR-21, RNU6B, and Sno234 were analyzed using two-step real-time PCR protocols 
with TaqMan MicroRNA Assays: hsa-miR-21 cod 000397; RNU6B cod 001093; 
snoRNA234 cod 001234  (Applied Biosystems). Reverse transcriptase reactions were 
performed using the TaqMan MicroRNA Reverse Transcription Kit (Applied 
Biosystems) in a 15 µL of total volume reaction mix with 7 µL of master mix containing 
1x RT buffer, 1.0 mM of total dNTPs, 50 U MultiScribe Reverse Transcriptase Enzyme, 
and 0.25 U of RNase inhibitor; 3 µL of RT primers (Applied Biosystems); and 5 µL of 
RNA sample. The amplification conditions were as follows: annealing at 16°C for 
30 min, extension at 42°C for 30 min, and RT inactivation at 85°C for 10 min. qPCRs 
were performed on Applied Biosystems Step One Plus Real-Time PCR System 
(Applied Biosystems) with a 20 µL final volume mixture containing 1x TaqMan 
Universal PCR Master Mix (Applied Biosystems), 1x MicroRNA Assay (Applied 
Biosystems), and 3 µ LcDNA (RT product diluted 1:5). Thermal cycling conditions 
were 10 min at 95°C followed by 40 cycles of 15 sec at 95°C and 1 min. at 60°C.The 
endpoint of qPCR data is the threshold cycle (Ct), which represents the fractional cycle 
number at which the fluorescence reaches the fixed threshold. All qPCR reactions were 
run in duplicate. The relative quantification of miRNA expression was analyzed using 
2−ΔΔCt method. 
 
6.10 Tumor xenografts 
To evaluate in vivo tumorigenesis, a BCC xenografting mouse model was established. 
After resuspension in PBS, 1×10-6 in 100 µl of CRISP-CTR BCC cells (control), one 
D3KO clone (D3KO n.12, Supplemental Figure 4), miR21 and D3KO-miR21 cells 
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were injected subcutaneously into the flanks of 5-week-old female BALB/c-nu mice. 
Mice were examined twice a week, and the tumor was measured with a caliper and then 
weighed three weeks after injection. All animals were maintained in a sterile 
environment on a daily 12 h light/12 h dark cycle. Tumor volume was calculated 
according to the formula, volume (mm3) = 4/3 x p x (length/2) x (width/2) x (height/2). 
Tumor xenografts were harvested, weighed, and snap-frozen for immunofluorescence 
analysis. 
 
6.11 Human samples 
Human BCC samples were collected at the Istituto Nazionale Tumori Ospedale Pascale 
in Naples. This work was approved by the appropriately constituted research ethics 
committee of the University of Naples Federico II.  
 
6.12 ChIP assay 
Approximately 8 × 106 cells were fixed with 1% formaldehyde in growth medium at 
37°C for 30 min. Glycine was added to a final concentration of 0.125 M to stop cross-
linking. Sonicated, cross-linked chromatin was centrifuged at 12,000 rpm for 30 min to 
remove insoluble material. The soluble chromatin was diluted 10-fold in dilution buffer 
and used directly for chromatin immunoprecipitation (ChIP) assays. Five percent of 
total DNA was used as a positive control for PCR assays (denoted “input DNA”). Six 
optical density (A260) units of chromatin from BCC cells were mixed with 10 µl 
(0.3 µg/µl) of anti-TRα and incubated at 4°C for 3 h before precipitation with protein 
A/G Sepharose (Sigma Chemical Co., St. Louis, MO). After five rounds of washing, 
bound DNA-protein complexes were eluted by incubation with 1% sodium dodecyl 
sulfate-0.1 M NaHCO3 elution buffer. Formaldehyde cross-links were reversed by 
incubation in 200 mM NaCl at 65°C. Samples were extracted twice with phenol-
chloroform and precipitated with ethanol. DNA fragments were recovered by 
centrifugation, resuspended in 50 µl of H2O, and used for real-time PCRs 
 
6.13 Isolation of epithelial CSCs 
Remove the dorsal skin from back of mice, gently scrape away the fat and blood vessels 
covering the dermis until the dermis is clearly and uniformly exposed. The dorsal skin 
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were plated on 10 mm dish, dermis side down, and incubated overnight in 0,25% 
trypsin at 4°C (Gibco). The next day the epidermis was separated from the dermis, 
chopped and incubated for 10 min in 0.25% trypsin at 37°C. Trypsin was neutralized by 
adding DMEM containing 10% Chelex serum. The cell suspension was then passed 
twice through a 70 µM cell strainer (Corning 431751). After isolation of keratinocytes, 
immunostaining was carried out using conjugated APC-anti-CD34 (clone MEC14.7; 
Biolegend) and PE-conjugated anti-α6- integrin (BD biosciences 555736). 
Living SmoM2-expressing epidermal cells were gated by forward scatter, by side 
scatter and by expression of SmoM2-YFP. Fluorescence activated, YFP+/α6- 
integrin+/CD34+ cell-sorting analysis was carried out using FACS Aria and FACS Diva 
software (BD Biosciences). Similarly, Tail skins were separated from the tail bone and 
processed as described above. 
 
6.14 Statistical analysis 
The results are shown as means ± SD throughout. Differences between samples were 
assessed by the Student’s two-tailed t test for independent samples. In all experiments, 
differences were considered significant when p was less than 0.05. Asterisks indicate 
significance at *p < 0.05, **p < 0.01, and ***p < 0.001 throughout. Differences of 
mRNA levels in human BBC samples versus normal skin samples were analyzed by 
using a one-way ANOVA, and P 0.05 was considered significant. Relative mRNA 
levels (in which the control sample was arbitrarily set as 1) are reported as results of 
real-time PCR, in which expression of cyclophilin A was used as a housekeeping gene. 
The relationship between the miR21/GRHL3, miR21/D3 and GRHL3/D3 expression 
was analyzed using Pearson’s correlation.  
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6.15 Sequences of primers 
 
Oligonucleotides used for plasmid generation and mutagenesis 
Name Sequence (5' → 3') 
mGRHL3clonU GCCGAAGCTTTCGAATGAACTTGATTTCAGGTC 
mGRHL3clonL TAATGAATTCTCATAGCTCCTTCAGGATGATC 
pmD3U GCCGGCTAGCTGTGAGCGCGCGCGGGAGGCGG 
pmD3L GCCGAGATCTGGTGGCCGCGGGCCCCGAAGCC 
mMiR21U ATTAGAGCTCATGTACAGGAGTTTCTGGGCA 
mMiR21L ATTACTCGAGCACACTGCTGTGGCACAAAGA 
pmD3mGRHLU GCGCGCGGGAAGCGCTCCGGCGCGGCGCT 
pmD3mGRHLL2 CCGCGCCGGAGCGCTTCCCGCGCGCCGCCGCCA 
pGL3biss ATTACGCCAGCCCAAGCTACC 
pGL3-R   AATTGTTCCAGGAACCAGGGCGTAT 
mHmir21dU ATTACCCGGGCACTGCCTCACTGTTTGCCATTG 
mHmir21dL GCCGCTCGAGCAAGCAAGCAGTTGCTTTCC 
mMir21mutU ACGCAGGGGTTGTTTTAATAAAAACTTAGATTGAGAA 
mMir21mutL TTCTCAATCTAAGTTTTTATTAAAACAACCCCTGCGT 
pmSox9U ATTACTCGAGCCTAGAGCTTCGCCCTCTTAG 
pmSox9L2 CGGCAAGCTTCTCTCTTGCAAAGAAAAGTTC 
Oligonucleotides used for genome analysis of CrispR/CAS clones 
gdio3U CGACCCAAGATTTCTGGGGCA 
gdio3L AGCAGAGTCTCAAGTTAGCCAGAC 
mHMIR21mutU ACGCAGGGGTTGTTTTAATAAAA 
mHMIR21wtU ACGCAGGGGTTGTCCTAATAAGG 
mHMIR21wtL CACACTGCTGTGGCACAAAGA 
Oligonucleotides used for Northern Blot 
MiR21probe TGGCAACAGCAGTCGATGGGCTGTCGGACAGAG 
5Sprobe TTAGCTTCCGAGATCAGACGAGGACAGAG 
OprobAAA TTTTTTTTTTCTCTGTCC 
Oligonucleotides used for real-time PCR 
Gene Forward primer (5' → 3') Reverse primer (5' → 3') 
cyclophilin A  CGCCACTGTCGCTTTTCG AACTTTGTCTGCAAACAGCTC 
CYCLOPHILIN A AGTCCATCTATGGGGAGAAATTTG GCCTCCACAATATTCATGCCTTC 
dio2 CTTCCTCCTAGATGCCTACAAAC GGCATAATTGTTACCTGATTCAGG 
dio3 CCGCTCTCTGCTGCTTCAC CGGATGCACAAGAAATCTAAAAGC 
thra1 CCTGGATGACACGGAAGTGGCT GGGCACTCGACTTTCATGTG 
thrb1/2 CACAGGGTACCACTATCGCTGC CAGCACCAAGTCTGTTGCCATGC 
mct8 TTCGGCTGGATAGTGGTGTTTGCA ATCATGCCCATAGCGAGGGCTC 
mct10 CCATCGTGAGTGTCTTCACGGACAT GGAGCAGGATTGTGAAGACGCTGC 
grhl3  TCATCGACGTAGCTGACTGT TTCATCATCGCGCATCTTCC 
GRHL3  TCATTGACGTGGCTGACTGC CTCGTCATCGCGCATCTTCC 
ptch1 ATTCCTTAATGGAAGTATTGC GCTCCTTGACTCAATAGATGA 
cyclin D1 GCTCCTGTGCTGCGAAGTGGA TCATGGCCAGCGGGAAGACCT 
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sox9 tcagcaagactctgggcaag actttgccagcttgcacgtcg 
krt17 CTTCCGTACCAAGTTTGAGAC CGGTTCTTCTCCGCCATCTTC 
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Introduction
Basal cell carcinoma (BCC) is the most frequently diagnosed 
human cancer and accounts for approximately 80% of all nonmel-
anoma skin cancers. BCC formation is based on a combination of 
inherited and environmental factors, mainly UV irradiation and 
long-term sun exposure. Proliferation and survival of BCC cells is 
physiologically regulated by the hedgehog (Hh) pathway, which 
plays a pivotal role in embryogenic development and tumorigenesis 
(1–4). Sporadic BCCs in humans are predominantly due to inacti-
vation of PTCH1, an inhibitor of Hh signaling, and the consequent 
activation of Gli transcription factors (5, 6). Therapeutics targeting 
Sonic hedgehog (SHH) signaling are now being used in patients and 
represent an important nonsurgical approach to interfere with BCC 
occurrence and growth (7).
Type 3 iodothyronine deiodinase (D3, encoded by the DIO3 
gene) is an oncofetal protein commonly deregulated in a wide range 
of adult tissues and re-expressed in cancer (8). D3 belongs to the 
deiodinase family of enzymes, which regulate thyroid hormone 
(TH) availability in target cells, thereby allowing the intracellular 
adaptation of the TH signal (9). The major product of the thyroid 
gland is T4, while the only active TH (T3) derives from the con-
version of T4 into T3 catalyzed by the deiodinases D1 and D2. D3 
degrades T4 and T3 into inactive metabolites and is thus the major 
physiological inactivator of TH (9). D3 is overexpressed in BCCs 
of both mouse and human origin, and is under the control of SHH, 
which increases D3 expression by acting via a conserved GLI2 bind-
ing site on the human DIO3 promoter (10). By decreasing TH action 
in the BCC microenvironment, D3 promotes BCC tumorigenesis. 
In addition, GLI2 and the SHH pathway are negative targets of TH, 
which thus attenuates cancer formation (11).
Among all cancer-related microRNAs (miRNAs), miR21 has 
been related to the pathogenesis of various malignant tumors, 
including prostate, gastric, colon, breast, and lung cancer (12–20). 
Apart from being involved in cancerogenesis, miR21 plays a cru-
cial role in a plethora of biological functions and diseases, namely 
development, cardiovascular diseases, and inflammation (21). 
miR21 is also expressed in skin (22–24), and its potential role as a 
regulator of skin homeostasis is demonstrated by its upregulation 
in such diseases as psoriasis, atopic dermatitis (25, 26), melanoma, 
and squamous cell carcinoma (SCC) (27–29). However, nothing is 
known about miR21 expression in BCC.
GRHL3 is a transcription factor expressed in the skin in the 
differentiated suprabasal layers, and is essential for epidermal 
differentiation and barrier formation at the end of mouse embryo-
genesis (30–33). Grhl3 KO mice exhibit impaired epidermal dif-
ferentiation and decreased expression of several genes involved 
in barrier formation (32). Accordingly, in humans, dominant-neg-
ative GRHL3 mutations are associated with defective periderm 
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in the tumor microenvironment. Disruption of this regulation in 
vivo drastically attenuates the oncogenic potential of BCC cells. 
Indeed, targeted mutagenesis of D3 potently reduces the tum-
origenic ability of BCC cells and of miR21-overexpressing BCC 
cells in a xenograft mouse model. Furthermore, genetic D3 deple-
tion in the keratinocyte compartment drastically reduced forma-
tion of BCC-like tumors in a GLI2-driven mouse model.
Together, our results provide what we believe to be novel 
insight into the function of TH in regulating the skin tumorigenic 
program and reveal a general mode of TH downregulation by 
oncogenic signals.
development in Van der Woude syndrome (34). Moreover, GRHL3 
was found to be a potent tumor suppressor in mouse and human 
SCC, and an upstream regulator of PTEN (31).
In this study we demonstrate that miR21 is a negative TH tar-
get. Moreover, besides being regulated by TH, miR21 also modu-
lates TH metabolism by inducing D3 expression. Importantly, we 
found that a miR21 target gene, GRHL3, which is essential for kera-
tinocyte differentiation, is a novel suppressor of D3 to our knowl-
edge and accounts for the positive regulation of miR21 on D3 levels.
Our data demonstrate the existence of a miR21/GRHL3/
D3 regulatory circuit that leads to a reduction of the TH signal 
Figure 1. TH represses miR21 in mouse and human BCC. (A) Genome-wide miRNA expression analysis in D3-depleted and control BCC cells. All the deregu-
lated miRNAs in shD3 relative to control cells are plotted against the P value. mmu-miR21, murine miR-21. (B) miR21 expression was measured by TaqMan 
real-time PCR in cDNAs from control BCC, shD3, and BCC cells treated with 30 nM T3 for 48 hours. (C) Schematic structural organization of the miR21 gene 
(red) and the miR21 enhancer region. The expression of the thyroid hormone–responsive element (TRE) and its comparison between species are indicated 
below. (D) ChIP analysis of the interaction between TRα and the miR21 enhancer region. Chromatin extracted from BCC cells was immunoprecipitated 
using the indicated antibodies. (E) miR21 expression was measured by TaqMan PCR in BCC cells carrying a mutated TRE element in the miR21 region (mut-
TRE) and control BCC cells (WT) treated or not with 30 nM T3 for 48 hours. Right: Reduction of miR21 in T3-treated cells versus nontreated cells in WT cells 
and CRISPR/Cas9–mediated TRE-mutated cells. *P < 0.05. Data represent the mean of at least 3 independent experiments in duplicate. SDs are indicated. 
Differences between samples were assessed by Student’s 2-tailed t test for independent samples.
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other TH signaling modulators (TRα and TRβ, MCT8 and MCT10) 
in BCC cells and in BCC cells transiently overexpressing miR21. 
While DIO2 mRNA, the TH receptors, and the transporters were 
not modified by miR21 expression (Supplemental Figure 3), over-
expression of miR21 strongly over induced D3 levels in a time- 
dependent manner (Figure 2A and Supplemental Figure 3).
We then inhibited miR21 in BCC cells by transfecting the 
LNA oligonucleotide complementary to miR21 (anti-miR21). In 
accordance with its role as an inducer of D3 expression, miR21 
inhibition potently reduced D3 expression at the mRNA and pro-
tein levels (Figure 2B). Importantly, overexpression of miR21 also 
attenuated intracellular TH action as indicated by the cotransfec-
tion of increasing amounts of miR21 together with an artificial 
T3-responsive promoter (Figure 2C).
miR21 induces D3 expression by targeting the tumor suppres-
sor GRHL3. miRNAs often inhibit mRNA expression at the post-
transcriptional level. Since D3 is induced by miR21, we tested the 
hypothesis that a direct miR21 target, and putative suppressor of D3, 
might mediate this effect. To this aim, we searched for miR21 down-
stream targets that could potentially inhibit D3 expression. By using 
the computational algorithm TargetScan (http://www.targetscan.
org/) together with published and/or validated miR21 target genes, 
we obtained a list of genes potentially controlled by miR21 (Sup-
plemental Table 2). This list was further analyzed with the DAVID 
program for functional classification (36). By selecting the categories 
of “Regulation of transcription,” “Epidermal development,” and 
“Tumor suppressor,” we found only a few genes that were present 
in all these 3 categories (Figure 2D). We tested the ability of 3 differ-
ent genes belonging to these categories, TP63, KLF5, and GRHL3, to 
affect D3 expression. Among these, only 1 gene repressed D3 expres-
sion, namely GRHL3 (Figure 2E and Supplemental Figure 4).
GRHL3 is a tumor suppressor functionally related to SCC for-
mation (31, 33). We first evaluated the expression of GRHL3 in 
BCC and normal skin, and, as shown in Supplemental Figure 5A, 
we observed that GRHL3 is highly expressed in normal skin and 
in WT keratinocytes, while it is repressed in BCC tissues and cells. 
We also tested whether GRHL3 is a miR21 downstream target in 
the BCC cells, as already demonstrated in other cell contexts (31). 
BCC cells transfected with miR21 or with anti-miR21 LNA (shown 
in Figure 2, A and B) were analyzed for GRHL3 mRNA and pro-
tein expression. miR21 overexpression reduced GRHL3, while 
miR21 silencing increased GRHL3 levels, thus validating GRHL3 
as a miR21 target in the BCC cell context (Supplemental Figure 6). 
Importantly, the same effects were observed in primary cultures 
of keratinocytes, in which, thanks to the very low level of endoge-
nous miR21, overexpression of miR21 changed DIO3 and GRHL3 
to a much greater extent than it did in BCC cells (Figure 2F).
To determine whether GRHL3 indeed negatively regulates D3, 
we knocked down the endogenous protein using 2 different siRNA 
oligos (siGRHL3-1 and siGRHL3-2). D3 levels were significantly 
higher in BCC cells transfected with 1 or more siGRHL3 oligos 
than in BCC cells transfected with scrambled oligos (siCTR). This 
result confirms that GRHL3 is a repressor of D3 expression (Figure 
2G and Supplemental Figure 5B).
We next tested whether GRHL3 directly binds to the Dio3 
promoter. In silico analysis revealed a putative GRHL3 binding 
site within the promoter region of the Dio3 gene (G1: GCGAAC-
Results
TH regulates the expression of multiple miRNAs and, in particular, 
downregulates miR21 in BCC. We previously showed that TH regu-
lates the proliferative potential of BCC cells in vitro and in vivo (10, 
11). To explore whether TH action in BCC involves the regulation of 
miRNAs, we analyzed the differential expression of mature miRNAs 
(miChip) in D3-silenced mouse BCC cells. We used a microarray 
platform of miRNA, the Exiqon platform (miRCURY LNA Arrays; 
Exiqon, Denmark), to compare the expression of miRNAs in BCC 
cells transfected with a control scrambled shRNA oligo versus 
the D3-targeting shRNA oligo (10). This analysis showed that 46 
miRNAs were differentially expressed (Supplemental Table 1; sup-
plemental material available online with this article; doi:10.1172/
JCI84465DS1). Among them, we selected miR21 for further studies, 
since it is overexpressed in a wide variety of cancers and has been 
causally linked to cell proliferation, apoptosis, and migration (12, 13), 
and, importantly, it is the most sensitive target upon D3 depletion 
(variation of 6.62-fold; Figure 1A and Supplemental Table 1).
We validated miR21 as a negative TH target gene by mea-
suring the mature miR21 transcript by TaqMan RT-PCR and by 
Northern blotting of BCC cells treated with TH (30 nM T3), and 
in D3-depleted BCC cells (shD3) (10), in which the TH signal 
was amplified (Figure 1B and Supplemental Figure 1A). Accord-
ingly, while repressed by TH treatment and D3 depletion, miR21 
was upregulated by D3 overexpression and by TH deprivation in 
serum (Supplemental Figure 1, B and C). To explore the possi-
bility that TH directly inhibits miR21 transcription, we analyzed 
the sequence of the miR21 enhancer region (35). In silico analysis 
revealed a conserved thyroid hormone–responsive element–bind-
ing (TRE-binding) site within the enhancer (Figure 1C). We cloned 
389 bp of the enhancer within the pGL3-basic vector to perform 
functional studies in the human embryonic kidney (HEK) 293 cell 
line and in mouse BCC cells. As shown in Supplemental Figure 2, 
A and B, the miR21 enhancer was efficiently downregulated by TH 
and by double thyroid receptor transfection/TH treatment in both 
cell lines, thus demonstrating that TH represses the transcription 
of the pre-miR21. ChIP analysis revealed that the thyroid recep-
tor (TR) physically binds to the newly identified TRE (Figure 1D). 
Furthermore, we mutagenized the core motif of the TRE within 
the miR21 enhancer region using CRISPR/Cas9 technology in the 
BCC cells. Effective mutagenesis was confirmed by sequencing of 
the DNA of clones containing the mutated TRE. One of the posi-
tive clones was treated with T3, and miR21 expression was mea-
sured using TaqMan PCR. As shown in Figure 1E, the endogenous 
miR21 was expressed at higher levels in cells with mutated TRE 
when compared with the control, WT BCC cells. Furthermore, 
the repression of miR21 by T3 was partially reduced in cells with 
mutated TRE, which demonstrates that mutation of the TRE 
attenuates the effect of T3 on miR21 (Figure 1E, right). The fact 
that TRE mutation does not completely abolish the regulation of 
T3 on miR21 suggests the existence of multiple TREs in other parts 
of the miR21 regulatory elements. Together, these results point to 
a negative regulation of T3 on the miR21 transcription via a direct 
T3-TR binding to the miR21 enhancer.
miR21 positively regulates D3 expression. Next, we explored the 
potential of miR21 to modulate the TH signal in BCC cells. To this 
aim, we measured the expression of deiodinases D2 and D3 and 
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Figure 2. miR21 upregulates D3 expression by targeting GRHL3. (A) BCC cells were transiently transfected with miR21 expression plasmid, and cells 
were collected at the indicated times. D3 mRNA and protein were measured by real-time PCR and Western blot (see complete unedited blots in the 
supplemental material). (B) LNA anti-miR21 or a control LNA-scrambled oligo was transfected in BCC cells, and D3 mRNA and protein were measured 
as in A. (C) BCC cells transfected with the artificial T3-responsive promoter TRE3-TK-Luc and CMV-renilla as internal control. Increasing amounts of 
miR21 were cotransfected, and cells were analyzed for luciferase activity. The results are shown as means ± SD of the luciferase/renilla (LUC/Renilla) 
ratios from at least 3 separate experiments, performed in duplicate. (D) miR21 target genes were classified for functional classification with the DAVID 
program (36). (E) D3 protein levels were measured by Western blot in BCC cells transfected with Flag-GRHL3 and harvested at the indicated times. 
GRHL3 (anti-Flag) and tubulin levels were measured as control. (F) Primary cultures of keratinocytes were transfected with miR21, and cells were 
harvested at 48 and 72 hours. Dio3 and Grhl3 mRNAs were measured by real-time PCR. (G) BCC cells were transfected with 2 different siRNAs targeting 
endogenous Grhl3 oligos or a combination of them, and D3 protein was measured by Western blot analysis. (H) Schematic representation of the Dio3 
locus, the Dio3 promoter, and the G1 site (red) responsive to GRHL. (I and J) BCC cells were transiently transfected with Dio3-Luc promoter (I) or Dio3-
Luc and mutDio3-Luc promoters (J) and with increasing amounts of the GRHL3 plasmid. Cells were harvested 48 hours after transfection and analyzed 
for luciferase activity. CMV-renilla was cotransfected as internal control. The results are shown as means ± SD of the LUC/renilla ratios from at least 3 
separate experiments, performed in duplicate. *P < 0.05.
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Furthermore, when the G1 site in the Dio3 promoter was mutated, 
miR21 failed to regulate D3 expression, thus reinforcing the find-
ing that GRHL3 is the only gene mediating miR21-dependent D3 
regulation (Supplemental Figure 6D). The picture that emerges 
from these results is that miR21 upregulates D3 expression by 
inhibiting the D3 repressor GRHL3.
Since TH negatively regulates miR21, we tested the possibility 
that TH treatment could in turn increase GRHL3 expression. Indeed, 
we observed that T3 treatment positively regulates GRHL3 and that 
this effect is mediated by miR21, as demonstrated by the results of 
T3 treatment and miR21 silencing shown in Supplemental Figure 7.
The identified miR21/GRHL3/D3 axis and its ability to modu-
late TH activity are depicted in Figure 3F.
BCC tumorigenesis requires an intact miR21/GRHL3/D3 axis. To 
assess the functional role of the newly identified network, we sought 
to disrupt the miR21/D3 axis by depleting D3 or by inducing miR21 
in a genetic Dio3-null background in vitro and in vivo. We used the 
CRISPR/Cas9 technology to genetically deplete D3 in BCC cells 
(D3KO clones). We also stably overexpressed miR21 in BCC cells 
(miR cells). One representative D3KO clone was subsequently stably 
transfected with the miR21 plasmid, and double D3KO-miR21-over-
expressing cells were selected (D3KO-miR cells). We first confirmed 
D3 depletion in D3KO clones (Supplemental Figure 8, A−C), and 
miR21 and D3 expression in miR cells (Supplemental Figure 8, D and 
E) and in double D3KO-miR cells (Supplemental Figure 8, F and G). 
CGGAGCT), which is highly conserved, and located 436 bp from 
the ATG codon (Figure 2H). Functional studies demonstrated that 
GRHL3 binds to the G1 site and represses the activity of the Dio3 
promoter. Indeed, cotransfection of the mouse Dio3 promoter 
(pmD3Luc) with increasing amounts of GRHL3 showed that the 
Dio3 promoter is potently inhibited by GRHL3 (Figure 2I). Muta-
tion of the G1 site within the Dio3 promoter revealed that, while the 
basal activity of the mutated promoter was increased as expected, 
the GRHL3-induced repression was abolished (Figure 2, I and J, 
and Supplemental Figure 6D). These data indicate that the tumor 
suppressor GRHL3 is a direct repressor of D3.
To assess the contribution of GRHL3 to the miR21-dependent 
D3 upregulation, we transfected miR21 or GRHL3 or both in BCC 
cells (Figure 3A). The forced expression of GRHL3 downregulated 
D3 expression and, most importantly, abolished the miR21-medi-
ated induction of D3 (Figure 3A). This observation was confirmed 
by a different approach, cotransfection of the Dio3 promoter with 
miR21 alone and with miR21 plus GRHL3. Also in this context, 
GRHL3 antagonized the effects induced by miR21 on D3 (Figure 
3C). Interestingly, concomitant miR21 overexpression and GRHL3 
downregulation by siRNA did not result in synergistic D3 upregu-
lation, which reinforces the concept that suppression of GRHL3 is 
the mechanism by which miR21 enhances D3 (Figure 3, B and D). 
Notably, miR21 and GRHL3 expression ultimately decreased and 
increased, respectively, the effect of TH in the nucleus (Figure 3E). 
Figure 3. The miR21/GRHL3 axis 
regulates D3 expression and TH 
intracellular concentration. (A) 
D3 protein levels were measured 
by Western blot from BCC cells 
transfected with miR21, GRHL3, 
and the 2 expression plasmids 
together. Lysates were also probed 
with anti-Flag antibody as control of 
Flag-GRHL3 transfection efficiency. 
(B) BCC cells were transfected with 
miR21 and miR21 plus 2 different 
siRNAs for GRHL3 knockdown. Anti-
GRHL3 antibody was used as internal 
control of GRHL3 knockdown. (C and 
D) The Dio3 promoter was cotrans-
fected with the indicated constructs 
together with CMV-renilla as internal 
control. Luciferase activity was 
measured and reported as means 
± SD of the LUC/renilla ratios from 
at least 3 separate experiments, 
performed in duplicate. (E) The 
T3-responsive promoter TRE3-TK-Luc 
was cotransfected in BCC cells with 
the indicated plasmids. Luciferase 
activity was measured as in C and D. 
*P < 0.05, **P < 0.01. (F) The miR21/
GRHL3/D3 axis regulates intracellular 
T3 availability.
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Because the level of miR21 was higher in BCC tissue than in normal 
skin (Figure 1, F and G), we tested whether the increase of miR21 
exceeded its basal levels of transcription. Indeed, we observed that 
miR21 is 10-fold overexpressed in miR clones versus control BCC 
cells (Supplemental Figure 8D). GRHL3 expression was very low in 
all generated cells and was further suppressed by miR21 overexpres-
sion (Supplemental Figure 8, H and I).
We next subcutaneously injected the cells generated into athymic 
(nude) mice and examined the weight and morphology of the result-
ing subcutaneous xenograft tumors. Tumors originating from miR 
cells grew rapidly, and were palpable 2 weeks after injection (Figure 
4, A and B). D3KO-miR cells generated much smaller tumors, which 
become palpable 3 weeks after injection, while D3KO cells did not 
generate tumors (Figure 4, A–C). Importantly, miR21 overexpres-
sion exacerbated tumorigenesis versus control BCC cells (Figure 4, 
A–C). On the contrary, D3 ablation almost completely abolished the 
tumorigenic advantage acquired upon miR21 overexpression; con-
sequently, D3 depletion results in a potent antitumoral effect even in 
the presence of an excess of miR21. We found a 3.54-fold reduction 
(D3KO-miR) and a 2.04-fold increase (miR21) in tumor weight, and 
a 4.2-fold reduction (D3KO-miR) and a 2.2-fold increase (miR21) in 
tumor volume, compared with control cell–generated tumors (Figure 
4, D and E). Accordingly, H&E, Ki-67, and TUNEL staining showed 
that control and miR-derived tumors have a high mitotic grade, while 
D3KO-miR–derived tumors showed multiple areas of cell death (Fig-
ure 4, F and G). Consistent with increased D3 expression in miR cells 
versus control cells, D3 mRNA and protein were upregulated in tumors 
overexpressing miR21 (Supplemental Figure 9). Furthermore, none of 
the generated tumors expressed GRHL3, thus confirming the tumor-
suppressor role of this transcriptional factor (Supplemental Figure 10).
Figure 4. Targeted D3 depletion drastically reduces the tumorigenic potential of BCC cells in nude mice. (A and B) 1 × 106 per 100 μl of control CRIS-
PR-CTR cells (CTR), stable miR21-overexpressing (miR) BCC cells, CRISPR/Cas9-D3KO cells (D3KO), and double D3KO-miR cells were injected s.c. into the 
flanks of nude mice. Mice were collected 3 weeks after injection, and tumors were measured as indicated in Methods. (C) Tumor volume was measured 
with a caliper for 3 weeks in CTR, miR, and D3KO-miR cells deriving tumors. (D and E) Tumor weight and volume measured 3 weeks after cell injection. (F 
and G) Tumor sections were analyzed by H&E staining and by immunofluorescence for Ki-67 and TUNEL expression in the indicated tumors. Scale bars: 
100 μm. Right: Percentage of Ki-67–positive and TUNEL-positive cells. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 5. Epidermal D3 depletion significantly reduces Gli2-driven BCC-like tumor formation and inhibits miR21 expression. (A) Genetic D3 depletion was 
specifically induced in keratinocytes by crossing of K5-Gli2 K14-Cre–/+ with Dio3fl/fl mice. (B) Mice were analyzed at 6 months of age when BCC-like formations 
were abundant and readily visible on the ears of control (Gli2) mice (n = 11). (C) Histological analysis of ears from Gli2 and Gli2;D3KO mice. H&E stainings were 
performed on sections of ears from Gli2 and Gli2;D3KO mice. Scale bars: 100 μm. (D) Immunofluorescent staining for PTCH1, K17, K10, and D3 expression. Scale 
bars: 100 μm. (E) Real-time PCR analysis to measure the expression of the indicated genes in Gli2 versus Gli2;D3KO mice (n = 7). (F and G) miR21 and Grhl3 
expression was measured in the ears from Gli2 and Gli2;D3KO mice (n = 7). (H) Schematic representation of the mutual, negative-feedback loop by which TH 
regulates miR21 and miR21 controls intracellular TH through GRHL3. *P < 0.05, **P < 0.01.
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inverse correlation between miR21 and GRHL3 and between D3 
and GRHL3; conversely, miR21 expression and D3 expression 
were linked by a positive correlation (Figure 6, D–F; miR21 vs. 
GRHL3: R = –0.35, P = 0.048; miR21 vs. D3: R = 0.5, P = 0.0049; 
GRHL3 vs. D3: R = –0.35, P = 0.048). The inverse correlation 
between miR21 and GRHL3 is in line with the demonstration by 
Bhandari et al. that miR21 negatively regulates GRHL3 in skin 
(33). Taken together, these results confirm the model established 
in our study and suggest that targeting D3 and increasing the TH 
signal might represent a therapeutic approach to BCC.
Discussion
Here we describe what we believe to be a novel network by which 
TH signaling, by modulating miRNA expression, interacts with 
oncogenic pathways to regulate the growth of BCC tumors. T3 
suppresses miR21 expression, thus attenuating BCC, and is con-
textually regulated by miR21 through the control of the TH-inac-
tivating enzyme D3. These conclusions are supported by genome-
wide, biochemical, and expression data coupled with functional 
studies in vivo in xenografts and in a BCC mouse model.
TH deregulation is frequent in human tumors, but it is not 
known whether it is a bystander event or whether it might drive 
or control cancer growth in vivo. Notably, the TH-inactivating 
enzyme D3 is upregulated in many human tumors and cancer 
cell lines (8). Determining the role of TH in cancer is challeng-
ing, mostly because TH plays pleiotropic roles in the body and it 
has been shown to trigger distinct, even opposing, functions in 
different cellular districts. On the basis of in vitro findings and 
studies conducted with a xenograft model, we previously reported 
that TH induces apoptosis and inhibits cell-cycle progression in 
BCC (10, 11). Our present findings complement these previous 
reports and extend the function of TH in BCC to the control of 
miR21- dependent oncogenic action. Importantly, using a unique 
skin-specific Dio3 KO mouse model, we provide the first in vivo 
genetic evidence that D3 depletion, which is equivalent to TH 
treatment, drastically reduces BCC formation.
TH signaling, miR21, and cancer. The classical mode of TH 
action is mainly mediated by nuclear receptors, the TRs, which 
are ligand-dependent transcription factors that bind to TREs in 
the promoter of target genes. In the absence of the ligand, TRs 
are associated with corepressors and with histone deacetylases, 
thereby preventing transcription. Upon T3 binding, the repres-
sive complex is destabilized and corepressors are replaced by 
coactivators that ultimately recruit RNA polymerase II in tran-
scription of target genes (38). Many cell cycle–related and pro-
liferation-controlling genes are TH targets, and, as such, TH 
positively or negatively controls cell proliferation and differen-
tiation in various contexts (8). Moreover, TH signaling is often 
compromised in carcinogenesis as demonstrated by the reduced 
expression or deletion of TR genes in human cancers, which sug-
gests that TRs could function as tumor suppressors. The inverse 
association between TH and cancer was confirmed by the find-
ings that the v-erb-a oncogene, which is the avian erythroblas-
tosis gene, is a mutated form of the THRA gene (coding for the 
TRα protein) (39), and that v-erb-a antagonizes T3 function in 
avian erythroblastosis virus–transformed erythroleukemic cells, 
thereby blocking T3-dependent cell differentiation (40).
Genetic D3 depletion potently reduces BCC-like tumor growth in 
vivo. Having shown that D3 depletion drastically attenuates BCC 
tumorigenesis and miR21 oncogenic potential in xenografts, we 
evaluated the role of D3 depletion in genetically induced BCC 
tumors in vivo. To this aim, we generated a keratinocyte-specific 
conditional D3-null mouse (K14-Cre+/– Dio3fl/fl) in a mouse model 
developing BCC-like tumors (K5-Gli2) (37), thereby generating 
a spontaneously forming mouse BCC-like model in an epider-
mal-specific D3-null background, namely, K5-Gli2 K14-Cre+/– 
Dio3fl/fl, henceforth referred to as “Gli2;D3KO” (Figure 5A), while 
K5-Gli2 K14-Cre–/– Dio3fl/fl mice (referred to as “Gli2”) served as 
controls. Constitutive activation of GLI2 in keratinocytes of Gli2 
mice resulted in epidermal hyperplasia, BCC, and basaloid follic-
ular hematoma with conspicuous down-growth, arising mostly on 
the ears of mice at 6 months of age (Figure 5, B and C, and Sup-
plemental Figure 6). Strikingly, Dio3 deletion in Gli2;D3KO mice 
reduced the number and size of tumors (Figure 5, B and C, and 
Supplemental Figure 6). The few lesions that developed on the 
ears of Gli2;D3KO mice were much smaller than those found in 
Gli2 mice. Expression of the BCC markers K17 and PTCH1 and 
SOX9 was drastically reduced in D3-depleted mice as measured 
by immunofluorescence and RT-PCR (Figure 5, D and E). Addi-
tionally, K10, a marker of the differentiating layers of the epider-
mis, was significantly downregulated in Gli2 mice, while it was 
well preserved in Gli2;D3KO mice (Figure 5D).
We next evaluated whether, by enhancing TH levels, D3 abla-
tion in skin could affect the expression of miR21 and GRHL3 in 
the tumor. As shown in Figure 5, F and G, miR21 was drastically 
reduced upon D3 depletion, while GRHL3 was upregulated in the 
absence of D3.
The data reported in this section indicate a functional require-
ment of D3 for growth in Hh pathway–driven skin tumors. These 
data also suggest that effective D3 loss and consequent TH activa-
tion lead to a remarkable attenuation of miR21 expression in vivo 
in BCC and a corresponding increase in the miR target GRHL3, 
and functionally validate our model of a reciprocal regulation 
of TH on miR21 and miR21 over TH metabolism in skin. The 
TH-miR21 interplay is schematically represented in Figure 5H.
The miR21/GRHL3/D3 axis is recapitulated in human BCC. 
Lastly, we sought to address whether the regulation of T3 on miR21 
and GRHL3 is recapitulated also in human BCC. To this aim, we 
evaluated miR21 levels in 16 human BCC tissues versus samples of 
healthy skin from the same patients by TaqMan real-time RT-PCR. 
In accordance with the concept that miR21 is a marker of tum-
origenesis, miR21 was expressed at significantly higher levels in 
BCC tissue than in the healthy skin samples (12.05-fold, P = 6.2 × 
10−8; Figure 6A). Similar miR21 overexpression in tumors occurred 
in mouse BCC cells and tumors (Supplemental Figure 11). We also 
measured GRHL3 and DIO3 expression in the human samples 
(Figure 6, B and C). As expected, GRHL3 was highly expressed in 
normal skin and drastically repressed in most of the BCC samples. 
D3 expression correlated with miR21 expression (Figure 6C).
Considering that miR21 and D3 are upregulated in human 
BCC, and GRHL3 is remarkably lower in BCC than in nontumor 
tissues, we performed a correlation analysis between miR21/
GRHL3, miR21/D3, and GRHL3/D3 expression in BCC tissues. 
Using Pearson’s correlation analysis, we observed a significant 
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miR21 is induced during immune cell activation (21, 43). The anal-
ogy of miR21 with D3 expression in multiple settings suggests that 
the miR21/D3 axis is a potential therapeutic target.
Although thyroid dysfunctions affect the skin phenotype and 
many people with hypothyroidism and hyperthyroidism have 
skin-related conditions (44), there is no evidence of an association 
between thyroid dysfunctions and BCC formation. This apparent 
lack of an association may be explained in 1 of 2 ways. Firstly, BCCs 
grow very slowly, while alterations of TH circulation at plasma 
levels are acute conditions that generally do not become chronic. 
Secondly, the deiodinase family represents a potent homeostatic 
mechanism when thyroid dysfunction induces a minimal varia-
tion of TH, and is thus able to preserve intracellular “normal” T3 
concentrations even in the presence of altered thyroid status at 
plasma level. Conversely, D3 upregulation in the BCC might not 
alter circulating TH concentrations.
The tumor suppressor GRHL3 is an inhibitor of D3. Our data 
demonstrate that the developmental factor and tumor suppressor 
GRHL3 represses DIO3 transcription and mediates the positive 
In this perspective, our finding that TH exerts negative control 
over miR21 expression is particularly relevant. miR21 is one of a 
handful of key miRNAs that promote human and mouse oncogen-
esis (12–20). Here, we provide what is to our knowledge the first 
evidence that miR21 is overexpressed in human and mouse BCC, 
while it is barely detectable in normal skin (Figure 6 and Supple-
mental Figure 11). Our data demonstrate that miR21 is suppressed 
by TH at the transcriptional level by directly binding to a TRE 
located within the miR21 enhancer region. Decreased expression 
of D3 or TH treatment of BCC cells contributes to downregulation 
of miR21 levels (Figure 1 and Supplemental Figure 1). Furthermore, 
our finding that miR21 is also an upstream regulator of D3 (Figure 
2) highlights the existence of a reciprocal TH-miR21 interplay, 
which regulates skin tumorigenesis.
Besides in cancer, there are many other contexts in which 
miR21 functions, D3 expression, and TH metabolism are linked. 
For instance, miR21 is implicated in many types of cardiac stress, 
including the myocardial remodeling that occurs after infarc-
tion, in which both D3 and miR21 are induced (41, 42). Moreover, 
Figure 6. miR21 inversely correlates with GRHL3 and is positively correlated with D3 in human BCCs. (A–C) The expression of miR21, GRHL3, and DIO3 
was measured in 16 human BCC tumors compared with normal skin counterparts. All samples were run in triplicate and referred to normal skin in sample 
1 set arbitrarily as 1. P values were calculated by 1-way ANOVA, *P < 0.05. (D–F) The same data as in A–C were reported as scale bars, and correlations 
between miR21/GRHL3, miR21/D3, and D3/GRHL3 were calculated by Pearson’s correlation analysis (bottom).
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in our D3- depleted mice contained very low levels of miR21, but 
substantially increased GRHL3 expression. D3 depletion potently 
attenuates BCC growth driven by the Shh/Gli2 pathway and by 
miR21 overexpression. However, although in a drastically attenu-
ated fashion, BCC cells still generate tumors when miR21 is over-
expressed and D3 is depleted, thus suggesting that increasing the 
intracellular TH signaling is not sufficient to eradicate BCC tum-
origenesis. Collectively, these data are consistent with a strong link 
between miR21 expression and D3 overexpression, and an inverse 
correlation between D3 and GRHL3. Moreover, they suggest the 
existence of a common route by which tumor cells attenuate the 
TH signal in the tumor microenvironment (Figure 5H).
In conclusion, our findings demonstrate that TH functions as 
a suppressor of BCC tumors by regulating multiple pathways, irre-
spective of miR21, and identify the TH-inactivating enzyme D3 as 
a potential target of anticancer therapy for human BCC.
Methods
Cell cultures and transfections. BCC cells were derived from transgenic 
mice expressing a constitutively active form of Gli2 under the control of 
the keratin 5 promoter, as previously described (49). BCC cells were cul-
tured under low-calcium conditions with 8% Ca2+-chelated fetal bovine 
serum (FBS) and keratinocyte growth factor (Sigma-Aldrich). HEK-293 
cells were cultured in DMEM with 10% FBS, 2 mM l-glutamine, and 10 
U/ml penicillin/streptomycin. All transient transfections for BCC cells 
were performed using Lipofectamine 2000 (Life Technologies) accord-
ing to the manufacturer’s instructions. HEK-293 cells were transfected 
using IBAfect reagent (IBA BioTAGnology). Mouse primary keratinocytes 
were isolated from C57BL/6 newborn mice and cultured under low-cal-
cium conditions (0.05 mM) in the presence of 4% calcium-chelated FBS 
(Invitrogen) and EGF (Invitrogen) as previously described (50).
Plasmids, siRNA, and reagents. Two luciferase-driving constructs 
(pmD3Luc and miR21-Enhancer-Luc) were generated as follows: For 
the pmD3Luc (Dio3 promoter) a genomic mouse DNA was used as a 
PCR template; the oligonucleotides pmD3U and pmD3L (Supplemen-
tal Table 3) generated a 750-bp fragment containing the mouse Dio3 
5′ flanking region. For the miR21-Enhancer-Luc plasmid, we used 
the oligos mMiR21U and mMiR21L to amplify 389 bp of the miR21 5′ 
flanking region (35). The amplified regions were cloned into the NheI/
BglII (pmD3Luc) or SacI/XhoI (miR21-Enhancer-Luc) sites of a pGL3- 
basic vector (Promega Corp.). The mutated plasmid pmD3Luc-del was 
obtained from the pmD3Luc by recombinant PCR with 2 sets of olig-
onucleotides. Briefly, the 2 PCR products, pmD3U/pmD3mGRHLL2 
and pmD3mGRHLU/pmD3L to obtain pmD3Luc-del, were combined 
by PCR using outside oligonucleotides, and the final PCR products 
were reinserted into the pGL3-basic vector (Promega Corp.). The 
Flag-GRHL3 plasmid was generated by PCR on mouse normal skin 
cDNA; the coding sequence of mouse Grhl3 was amplified by PCR with 
specific oligonucleotides (mGRHL3clonU and mGRHL3clonL); the 
PCR product was inserted into the HindIII/EcoRI sites of the pFLAG-
CMV-2 vector (Sigma-Aldrich). GRHL3 silencing was performed with 
siRNA technology: 2 siRNAs targeting GRHL3 were purchased from 
Life Technologies (catalog s106644, s106646). Stealth RNAi nega-
tive control duplex (Invitrogen) served as control. Effective GRHL3 
silencing was confirmed by measurement of GRHL3 protein levels in 
transfected cells (Supplemental Figure 4B). The primer sequence is 
reported in Supplemental Table 3. The miR21-overexpressing plasmid 
regulation of D3 expression by miR21. Although GRHL3 has been 
shown to be a miR21 target gene in SCCs (31, 33), this regulation 
appears to be context-dependent, since it was not among the 
miR21 targets in tissues in which miR21 was modified (45). Here we 
demonstrate that GRHL3 is downregulated by miR21 in BCC (Fig-
ures 2 And 3). Accordingly, GRHL3 inhibition increases the expres-
sion of D3 in BCC cells. This is consistent with the poor expression 
of D3 in adult tissues and its reactivation in many tumoral con-
texts (8). Remarkably, forced GRHL3 expression prevents miR21- 
dependent D3 transcription, thus providing genetic evidence for a 
miR21/GRHL3/D3 epistatic cascade (Figure 3, A–D).
The discovery of a miR21/GRHL3/D3 axis prompts some 
considerations regarding the role of TH metabolism in the skin. 
First, both miR21 and GRHL3 (which are functionally related to 
D3 expression) play critical roles in different skin cancer subtypes 
(33, 46). These observations reinforce the concept that D3 expres-
sion and TH metabolism play a critical role in skin cancer. Second, 
we previously demonstrated that D3 overexpression amplifies 
keratinocyte proliferation (10), and while its expression is very 
low in adult tissues, D3 is re-expressed in many hyperproliferative 
conditions (8). The inverse correlation between D3 and GRHL3 in 
BCC emphasizes the opposite roles played by the 2 genes in BCC 
tumorigenesis and, most importantly, suggests that the negative 
control exerted by GRHL3 on D3 expression might be extended to 
such other pathological conditions as psoriasis and wound healing 
in which GRHL3 plays a regulatory role (47, 48). Third, GRHL3 is 
critical for keratinocyte differentiation and skin barrier formation, 
and Grhl3–/– mice exhibit impaired epidermal differentiation and 
decreased expression of multiple differentiation genes (47). This 
implies that D3 suppression and increased TH signaling are also 
part of the differentiation program of keratinocytes. Should this be 
the case, it would be clinically relevant, since alterations of TH lev-
els in patients are associated with cutaneous manifestations, and 
generalized myxedema (increased glycosaminoglycan deposition 
in skin, which appears cold, dry, and pale, with abundant hair loss) 
is the classical clinical sign of hypothyroid patients (44). Further 
studies are needed to determine whether T3 directly affects skin 
barrier formation and hair follicle cycle regulation.
D3 depletion drastically reduces BCC tumorigenesis. To assess the 
pathological role of the newly identified circuit in vivo, we inhibited 
D3 by CRISPR/Cas9 technology in BCC cells and in miR21-over-
expressing BCC cells. These experiments demonstrated that block-
ade of D3 potently attenuates BCC cell proliferation and in vivo 
xenograft tumorigenesis. miR21 overexpression stimulated the 
oncogenic potential of BCC cells to a greater extent than control 
cells (Figure 4). Notably, although BCC cells were transduced with 
miR21, their ability to form tumors was significantly hampered by 
D3 ablation, which strongly supports the concept that the TH inacti-
vation pathway plays a pivotal role in tumor growth.
Intracellular TH regulation by D3 appears to be critical for 
tumorigenic potential in an in vivo model of BCC-like tumor for-
mation. Indeed, we demonstrate that skin-specific D3 depletion 
drastically reduces tumor occurrence in mice with spontane-
ously forming BCC tumors, and prevents miR21 overexpression 
in these tumors. Thus, our data demonstrate that blocking TH 
degradation at the cellular level is a new modality with which to 
interfere with skin tumorigenesis. The few tumors that developed 
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incubated with HRP-conjugated donkey anti-rabbit IgG secondary 
antibody (1:3,000), and detected by chemiluminescence (Millipore). 
After extensive washing, the membrane was incubated with anti-tubu-
lin-specific antibodies (sc-8035, 1:10,000; Santa Cruz Biotechnology 
Inc.) as loading control. All Western blots were run in triplicate, and 
bands were quantitated in 1 representative gel.
miRNA Northern blot. Total RNA was isolated from BCC cells 
treated or not with T3, using TRIzol (Invitrogen) and quantitated at 
260 nm using a standard spectrometry. Ten micrograms of total RNA 
was resuspended in 2′ Tris/borate/EDTA (TBE) urea sample buffer 
(Invitrogen) to a final volume of 10 μl. Samples were heated at 70°C 
for 5 minutes and loaded onto a 15% polyacrylamide gel containing 
TBE urea. Electrophoresis was performed in 1′ TBE running buffer at 
120 V with a run time between 60 and 90 minutes. After electropho-
resis, the gel was rinsed in deionized water, followed by a 5-minute 
wash in 1′ TBE. RNA was transferred onto a Hybond-N+ membrane 
for 30 minutes at 20 V using a Bio-Rad Miniprotean II apparatus. 
The nylon membrane was placed in the Stratagene UV Crosslinker 
and RNA cross-linked at 1,200 kJ. As miR21 probe, we designed the 
oligonucleotide MiR21probe (Supplemental Table 3) containing the 
mature miRNA sequence. The oligo was hybridized to the OprobAAA: 
5′-TTTTTTTTTTCTCTGTCC-3′, and elongated with Klenow exo– 
(Life Technologies) and ATP α-32P (PerkinElmer Inc.) to generate a tail 
of radioactive adenine. To normalize the RNA, we used the 5S subunit 
of rRNA (Supplemental Table 3), which was also hybridized to the 
OprobAAA and radiolabeled.
Animals, histology, and immunostaining. K5-Gli2 K14-Cre+/– Dio3fl/fl 
(Gli2;D3KO) mice were obtained by crossing of a keratinocyte-specific 
conditional D3-null mouse (K14-Cre+/– D3fl/fl) with the mouse model 
K5-Gli2 (37). Female 5-week-old BALB/c (nude) mice were purchased 
from Charles River Laboratories. All animal experiments and mouse 
husbandry were done in the animal facility at CEINGE-Biotecnologie 
Avanzate, Naples, Italy, in accordance with institutional guidelines. For 
immunofluorescence and histology, ears from Gli2;D3KO and control 
xenograft tumors of mice at 6 months of age were embedded in par-
affin, cut into 7-μm sections, and H&E-stained. Slides were baked at 
60°C, deparaffinized by xylenes, dehydrated with ethanol, rehydrated 
in PBS, and permeabilized by 0.5% Triton X-100 in PBS. Antigen 
retrieval was performed by incubation in 0.01 M citrate buffer (pH 
6.0) or 0.5 M Tris buffer (pH 8.0) at 95°C for 15 minutes. Sections were 
blocked in 1% BSA/0.05% Tween/PBS for 30 minutes at 37°C. Primary 
antibody incubation was carried out overnight at 4°C in blocking buffer 
followed by washing in 0.2% Tween/PBS. Secondary antibody incuba-
tion was carried out at room temperature for 1 hour, followed by wash-
ing in 0.2% Tween/PBS. Images were acquired with an IX51 Olympus 
microscope and the Cell*F Olympus Imaging Software.
Real-time RT-PCR. mRNAs were extracted with TRIzol reagent 
(Life Technologies). cDNAs were prepared with SuperScript VILO 
Master Mix (Life Technologies) as indicated by the manufacturer. The 
cDNAs were amplified by PCR in an iQ5 Multicolor Real-Time Detec-
tor System (Bio-Rad) with the fluorescent double-stranded DNA-bind-
ing dye SYBR Green (Applied Biosystems). Specific primers for each 
gene were designed to work under the same cycling conditions (95°C 
for 10 minutes followed by 40 cycles at 95°C for 15 seconds and 60°C 
for 1 minute), generating products of comparable sizes (~200 bp for 
each amplification). Primer combinations were positioned whenever 
possible to span an exon-exon junction and the RNA digested with 
was provided by G. De Vita (University of Naples Federico II, Naples, 
Italy). Knockdown of miR21 was performed by transient transfection of 
anti-miR21 LNA (ID mh10206; Ambion). LNA-scrambled CTR served 
as control. Western blot analysis was performed with the following 
antibodies: anti-D3 (D3-718; ref. 51), anti–cyclin D1 (sc-246; Santa Cruz 
Biotechnology Inc.), and anti-tubulin (sc-8035; Santa Cruz Biotechnol-
ogy Inc.). Anti-K17 (NCL-CK17; Novocastra), anti-K10 (PRB-159P), 
anti-Sox9 (ab26414; Abcam), and anti-PTCH1 (2113; Novus Biologi-
cals) antibodies were used for immunofluorescence experiments.
Genome editing of the Dio3 locus using the CRISPR/Cas9 system. 
Targeted depletion of D3 in mouse BCC cells was obtained with 
CRISPR/Cas9 technology using the CRISPR/Cas9 system from Santa 
Cruz Biotechnology Inc. (Dio3 CRISPR/Cas9 KO Plasmid, catalog 
sc-430733) and control plasmid (Control CRISPR/Cas9 Plasmid, cat-
alog sc-418922). The D3 CRISPR/Cas9 KO plasmid consists of a pool 
of 3 plasmids, each encoding the Cas9 nuclease and a target-specific 
20-nucleotide guide RNA. CRISPR/Cas9–guided mutagenesis in this 
case resulted in a deletion in the Dio3 coding region. Briefly, BCC cells 
were transfected with 500 ng of the D3 CRISPR/Cas9 KO plasmid or 
control plasmid with Lipofectamine 2000 (Life Technologies). Three 
days after transfection, the cells were FACS-sorted for GFP expres-
sion, and single clones were selected and analyzed by PCR to verify 
D3 coding sequence integrity using specific oligonucleotides (gdio3U: 
CGACCCAAGATTTCTGGGGCA; and gdio3L: AGCAGAGTCT-
CAAGTTAGCCAGAC; Supplemental Figure 4). Effective D3 deple-
tion was confirmed by Western blot analysis (Supplemental Figure 4).
Genome editing of the TRE in the miR21 enhancer using the CRISPR/
Cas9 system. Targeted mutagenesis of the TRE site within the miR21 
enhancer region was performed with CRISPR/Cas9 technology and 
the CRISPR/Cas9 system from ADDGENE [pSpCas9(BB)-2A-GFP]. 
We used 2 custom-designed synthetic single guide RNAs (sgRNAs) 
targeting the genomic region flanking the TRE site. Each sgRNA was 
cloned into the pX458 [pSpCas9(BB)-2A-GFP] vector, which also 
encodes the Cas9 nuclease (52). To obtain the mutated template, 
recombinant PCR was performed on the genomic mouse DNA (Sup-
plemental Figure 2) using 2 sets of oligos (mHmir21dU and mMIR-
21mutL; mMIR21mutU and mHmir21dL), which generated a 2-kb 
fragment containing the mutation TCCTAATAAGGA to TttTAAT-
AAaaA. The vector and the TRE-mutated sequence were transfected 
into BCC cells, and cells expressing GFP were sorted by FACS into 
individual wells of 96-well plates and expanded in culture. Successful 
homology directed repair–mediated mutation was assessed by PCR 
and Sanger sequencing.
Luciferase assays. The Luc plasmids (pmD3Luc, miR21-Enhancer-
Luc, or TRE3-TK-Luc) and CMV-renilla reporters were cotransfected 
into BCC and HEK-293 cells, and treated with 30 nM T3 as indicated. 
Luciferase activities were measured 48 hours after transfection using 
the Dual Luciferase Reporter Assay System (Promega Corp.), and dif-
ferences in transfection efficiency were corrected relative to the level 
of renilla activity. Each construct was studied in triplicate in at least 3 
separate transfection experiments.
Western blot analysis. Total protein extracts from BCC cells were 
run on a 10% SDS-PAGE gel and transferred on Immobilon-P transfer 
membrane (Millipore). The membrane was then blocked with 5% non-
fat dry milk in PBS, probed with anti-D3 polyclonal antibodies (1:500), 
anti-Flag (1:1,000, M2; Sigma-Aldrich), or GRHL3 antibody (1:500, 
sc-398839; Santa Cruz Biotechnology Inc.) for 2 hours, washed and 
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hour dark cycle. Tumor volume was calculated according to the for-
mula: volume (mm3) = 4/3 × π × (length/2) × (width/2) × (height/2). 
Tumor xenografts were harvested, weighed, and snap-frozen for 
immunofluorescence analysis.
Human samples. Human BCC samples were collected at the Isti-
tuto Nazionale Tumori Ospedale Pascale in Naples.
Statistics. The results are shown as means ± SD throughout. Differ-
ences between samples were assessed by Student’s 2-tailed t test for 
independent samples. In all experiments, differences were considered 
significant when P was less than 0.05. Asterisks indicate significance 
at *P < 0.05, **P < 0.01, and ***P < 0.001 throughout. Differences of 
mRNA levels in human BBC samples versus normal skin samples were 
analyzed using a 1-way ANOVA, and P less than 0.05 was considered 
significant. Relative mRNA levels (in which the control sample was 
arbitrarily set as 1) are reported as results of real-time PCR, in which 
expression of cyclophilin A was used as a housekeeping gene. The rela-
tionship between miR21/GRHL3, miR21/D3, and GRHL3/D3 expres-
sion was analyzed using Pearson’s correlation.
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deoxyribonuclease to avoid genomic DNA interference. For each reac-
tion, standard curves for reference genes were constructed based on 
six 4-fold serial dilutions of cDNA. All samples were run in triplicate. 
The template concentration was calculated from the cycle number 
when the amount of PCR product passed a threshold established in the 
exponential phase of the PCR. The relative amounts of gene expression 
were calculated with cyclophilin A expression as an internal standard 
(calibrator). The results, expressed as n-fold differences in target gene 
expression, were determined as follows: n × target = 2(ΔCtsample – ΔCtcalibrator).
miRNA microarray analysis. miRNA microarray analysis was per-
formed in BCC cells transfected with shD3 or shCTR stealth oligos. 
Briefly, total RNA was harvested using the TRIzol reagent (Invitrogen) 
according to the manufacturer’s instructions. The samples were hybrid-
ized to the miRCURY LNA Array (version 9.2; Exiqon). Data have been 
submitted to the Gene Expression Omnibus database (GEO GSE78265).
TaqMan miRNA assay. miR21, RNU6B, and Sno234 were analyzed 
using 2-step real-time PCR protocols with TaqMan MicroRNA Assays: 
hsa-miR-21 catalog 000397; RNU6B catalog 001093; SnoRNA234 
catalog 001234 (Applied Biosystems). Reverse transcriptase reactions 
were performed using the TaqMan MicroRNA Reverse Transcription 
Kit (Applied Biosystems) in a reaction mix of 15 μl total volume with 7 
μl of Master Mix containing 1′ RT buffer, 1.0 mM of total dNTPs, 50 U 
MultiScribe Reverse Transcriptase Enzyme, and 0.25 U of RNase inhib-
itor; 3 μl of RT primers (Applied Biosystems); and 5 μl of RNA sample. 
The amplification conditions were as follows: annealing at 16°C for 30 
minutes, extension at 42°C for 30 minutes, and RT inactivation at 85°C 
for 10 minutes. Quantitative PCRs (qPCRs) were performed on Applied 
Biosystems Step One Plus Real-Time PCR System with a mixture of 20 μl 
final volume containing 1′ TaqMan Universal PCR Master Mix (Applied 
Biosystems), 1 MicroRNA Assay (Applied Biosystems), and 3 μl cDNA 
(RT product diluted 1:5). Thermal cycling conditions were 10 minutes at 
95°C followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. 
The end point of qPCR data is the threshold cycle (Ct), which represents 
the fractional cycle number at which the fluorescence reaches the fixed 
threshold. All qPCR reactions were run in duplicate. The relative quanti-
fication of miRNA expression was analyzed using the 2−ΔΔCt method.
Tumor xenografts. To evaluate in vivo tumorigenesis, a BCC 
xenografting mouse model was established. After resuspension in PBS, 
1 × 106 in 100 μl of CRISPR-CTR BCC cells (control), 1 D3KO clone 
(D3KO n.12, Supplemental Figure 4), and miR21 and D3KO-miR21 
cells were injected s.c. into the flanks of 5-week-old female BALB/c-nu 
mice. Mice were examined twice a week, and the tumor was measured 
with a caliper and then weighed 3 weeks after injection. All animals 
were maintained in a sterile environment on a daily 12-hour light/12-
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The Concerted Action of Type 2 and Type 3 Deiodinases
Regulates the Cell Cycle and Survival
of Basal Cell Carcinoma Cells
AU1c Caterina Miro,1 Raffaele Ambrosio,2 Maria Angela De Stefano,1 Daniela Di Girolamo,1 Emery Di Cicco,1
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Luigi Del Vecchio,3 Domenico Salvatore,1,3,* and Monica Dentice1, 3,*
Background: Thyroid hormones (THs) mediate pleiotropic cellular processes involved in metabolism, cellular
proliferation, and differentiation. The intracellular hormonal environment can be tailored by the type 1 and 2
deiodinase enzymes D2 and D3, which catalyze TH activation and inactivation respectively. In many cellular
systems, THs exert well-documented stimulatory or inhibitory effects on cell proliferation; however, the mo-
lecular mechanisms by which they control rates of cell cycle progression have not yet been entirely clarified.
We previously showed that D3 depletion or TH treatment influences the proliferation and survival of basal cell
carcinoma (BCC) cells. Surprisingly, we also found that BCC cells express not only sustained levels of D3 but
also robust levels of D2. The aim of the present study was to dissect the contribution of D2 to TH metabolism in
the BCC context, and to identify the molecular changes associated with cell proliferation and survival induced
by TH and mediated by D2 and D3.
Methods: We used the CRISPR/Cas9 technology to genetically deplete D2 and D3 in BCC cells and studied
the consequences of depletion on cell cycle progression and on cell death. Cell cycle progression was analyzed
by fluorescence activated cell sorting analysis of synchronized cells, and the apoptosis rate by annexin V
incorporation.
Results: Mechanistic investigations revealed that D2 inactivation accelerates cell cycle progression thereby
enhancing the proportion of S-phase cells and cyclin D1 expression. Conversely, D3 mutagenesis drastically
suppressed cell proliferation and enhanced apoptosis of BCC cells. Furthermore, the basal apoptotic rate was
oppositely regulated in D2- and D3-depleted cells.
Conclusion: Our results indicate that BCC cells constitute an example in which the TH signal is finely tuned
by the concerted expression of opposite-acting deiodinases. The dual regulation of D2 and D3 expression plays
a critical role in cell cycle progression and cell death by influencing cyclin D1-mediated entry into the G1-S
phase. These findings reinforce the concept that TH is a potential therapeutic target in human BCC.
Keywords: deiodinases, thyroid hormone metabolism, basal cell carcinoma
Introduction
Thyroid hormone (TH) exerts pleiotropic effects dur-ing organ development and in adulthood by regulating
such cellular processes as cell survival and differentiation
and cellular homeostasis and metabolism (1,2). The active
thyroid hormone, triiodothyronine (T3), in the target tissues
can derive either from circulating T3 levels or from the in-
tracellular conversion of the prohormone thyroxine (T4) into
T3. Three iodothyronine deiodinase enzymes catalyze the
removal of the iodine moiety—a process that results in TH
activation or inactivation. Type 2 deiodinase (D2) is the TH-
activating enzyme in the skin, while type 3 deiodinase (D3)
terminates TH action and attenuates the signal. The canonical
action of T3 is to regulate gene expression by binding with
bAU4nuclear receptors (TRs) that are encoded by two genes, Thra
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and Thrb, thereby giving rise to different isoforms, whose
active receptors are TRa1, TRb1, and TRb2 (3). Nuclear
receptors bind to thyroid response elements (TREs) present
in the promoter regions of the target genes, thus forming
homo- or heterodimers with other nuclear receptors and fi-
nally resulting in activation or repression of transcription.
The actions of T3 are also modulated by co-repressors and
co-activators (3).
Thyroid hormone has been reported to be a critical regu-
lator of cell differentiation during development and in
adulthood (4). Accordingly, the TH inactivating enzyme, D3,
is overexpressed in several mouse and human cancers. This
concept is exemplified by basal cell carcinoma (BCC), which
is characterized by sustained D3 expression, and in which the
TH signal attenuates cell proliferation thereby reducing BCC
tumorigenicity (5). The skin is very sensitive to the action of
TH. Indeed, TH influences both epidermal homeostasis and
the pathogenesis of skin cancer (6). Moreover, normal TH
levels are required for efficient epidermal homeostasis,
function and regeneration (7). By binding to TRs, T3 regu-
lates the expression of several keratins and skin-specific
genes (8,9–11). This regulation is critical for fetal epidermal
differentiation, barrier formation, hair growth, sebum pro-
duction, wound healing, epidermal oxygen consumption, and
keratinocyte proliferation (8,12–14).
The molecular mechanisms by which TH regulates rates of
cell cycle progression and the relative contributions of
deiodinases in this process have not yet been completely
elucidated. We previously showed that D3 depletion and TH
treatment influence the proliferation and survival of BCC
cells. An intriguing and unexpected finding of the present
study was that D2 is also highly expressed in BCC, which
suggests that the D3-activating enzyme might play a role in
BCC tumorigenesis and that the regulation of BCC tumori-
genesis by TH can be more complex than previously thought.
The aim of the present study was to identify the molecular
changes associated with cell cycle progression and apoptosis
induced by TH and mediated by the deiodinases D2 and D3.
Our data provide evidence that the BCC cell population is a
unique cell model that is exquisitely sensitive to TH modu-
lation and expresses high levels of both activating (D2) and
inactivating (D3) TH enzymes. Co-expression of D2 and D3
raises the possibility of studying in detail the opposite effects
of intracellular TH modulation and is thus a cellular model
with which to unravel the molecular mechanisms of cell cycle
control by TH.
Materials and Methods
Cell cultures, transfections, and reagents
BCC cells (G2N2c) are derived from transgenic mice
expressing a constitutively active form of GLI2 under the
control of the keratin 5 promoter (15), which generates
BCC-like tumors called ‘‘trichoblastomas,’’ which are re-
ferred to as ‘‘BCC cells’’ throughout this article. Mouse
primary keratinocytes were purified from wild-type (C57)
mice and cultured under low-calcium conditions with 8%
Ca2+-chelated fetal bovine serum and keratinocyte growth
factor (Sigma-Aldrich, Saint Louis, MO) (16) Transient
transfections were performed with Lipofectamine 2000
(Life Technologies Ltd., Paisley, Scotland) according to
the manufacturer’s instructions. Monoclonal anti-cyclin D1
anti-Erk antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA). BCC cells were treated with 2.5 lM and
12.5 lM doxorubicin for 16 hours and with 0.2 lg/mL and
1lg/mL tunicamicin for 24 hours.
Dio2 and Dio3 targeted mutagenesis
Depletion of Dio3 and Dio2 in mouse BCC cells was ob-
tained using the CRISPR/Cas9 system from Santa Cruz
Biotechnology (Dio3 CRISPR/Cas9 Knockout [KO] Plas-
mid, catalog sc-430733; Dio2 CRISPR/Cas9 KO Plasmid,
catalog sc-420003) and control plasmid (Control CRISPR/
Cas9 Plasmid, catalog sc-418922) as previously described
(17). BCC cells were transfected with 500 ng of the D3, D2,
or control CRISPR/Cas9 KO plasmids with Lipofectamine
2000 (Life Technologies). Three days after transfection, the
cells were sorted bAU5using fluorescence activated cell sorting
(FACS) for green fluorescent protein expression, single
clones were analyzed by PCR to evaluate coding region al-
terations, and Dio2 exon 1 was sequenced to identify the
inserted mutations. D3KO and control cells have already
been checked for effective and specific D3 depletion as re-
ported in Di Girolamo et al. (17).
Western blot analysis
Total protein extracts from BCC cells were run on a 10%
SDS-PAGE gel and transferred onto an Immobilon-P
transfer membrane (Millipore). The membrane was then
blocked with 5% nonfat dry milk in phosphate-buffered
saline (PBS), probed with anti-cyclin D1 and anti-PARP
antibodies overnight at 4C, washed, and incubated with
horseradish peroxidase–conjugated anti-mouse immuno-
globulin G secondary antibody (1:3,000), and detected by
chemiluminescence (Millipore, cat. WBKLS0500). After ex-
tensivewashing, themembranewas incubatedwith anti-Erk or
anti-tubulin specific antibodies (Santa Cruz Biotechnology) as
loading control. All Western blots were run in triplicate, and
bands were quantified with ImageJ software.
Real-time PCR (RT-PCR)
Messenger RNAs were extracted with Trizol reagent (Life
Technologies Ltd). Complementary DNAs were prepared
with Vilo reverse transcriptase (Life Technologies Ltd.) as
indicated by themanufacturer. The cDNAswere amplified by
PCR in an iQ5 Multicolor Real Time Detector System
(BioRad, Hercules, CA) with the fluorescent double-stranded
DNA-binding dye SYBR Green (Applied Biosystems).
Specific primers for each gene were designed to work under
the same cycling conditions (95C for 10min followed by 40
cycles at 95C for 15 s and 60C for 1min), thereby gener-
ating products of comparable sizes (about 200 bp for each
amplification). Primer combinations were positioned when-
ever possible to span an exon–exon junction and the RNA
digested with DNAse to avoid genomic DNA interference.
Primer sequences are indicated in the b ST1Supplementary
Table S1 (Supplementary Data are available online at www.
liebertpub.com/thy). For each reaction, standard curves for
reference genes were constructed based on six four-fold serial
dilutions of cDNA. All samples were run in triplicate. The
template concentration was calculated from the cycle num-
ber when the amount of PCR product passed a threshold
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established in the exponential phase of the PCR. The relative
amounts of gene expression were calculated with cyclophilin
A expression as an internal standard (calibrator). The results,
expressed as N-fold differences in target gene expression,
were determined as follows: N *target = 2(Ct sample Ct calibrator).
Colony formation assay
To evaluate colony formation, cells were seeded out in
appropriate dilutions to form colonies. Three and six days
after plating, cells were washed with PBS and stained with
1% crystal violet in 20% ethanol for 10min at room tem-
perature. Cells were washed with PBS twice and visible
colonies were counted.
DNA transfection and Luciferase (Luc)
expression assays
G2N2C cells were transiently transfected using Lipofecta-
mine 2000 (Life Technologies Ltd.) according to the manufac-
turer’s instructions. The reporter plasmids (pCcnD1CTR-Luc
or T3TK-Luc) and CMV-Renilla were co-transfected into
G2N2C. Luc activities were measured 48 hours after trans-
fection with the Dual Luciferase Reporter Assay System
(Promega), and differences in transfection efficiency were
corrected relative to the level of Renilla Luciferase. Each
construct was studied in triplicate in at least three separate
transfection experiments.
Cell cycle analysis
For DNA content analysis, G2N2C cells were first syn-
chronized by a double thymidine block protocol (18). Briefly,
cells were grown in 100mm plates to 40–50% confluence and
then incubated for 14 h with growth medium supplemented
with 2mM thymidine. After two washes with PBS, cell me-
dium was replaced by growth medium without thymidine
for 24 h. Cells were then subjected to an additional incubation
with 2mM thymidine for 14 h followed by a release in growing
medium until harvesting at the indicated time points (F1c Fig. 1).
Cells were fixed in ice-cold 70% ethanol at -20C. At least
AU6c 10,000 cells were analyzed by FACS (FACS Canto2, Becton
Dickinson) after staining with 5lg/mL propidium iodide and
exposure to 0.25mg/mL RNase I (Sigma Aldrich). Data were
analyzed with the MODFIT Lt3.0 Software.
For carboxy-fluorescein succinimidyl ester (CFSE) in vivo
labeling, the CFSE labeling solution (1 lM) was added to
1mL cell suspensions in PBS and incubated for 10min at
room temperature, after which cells were washed with reg-
ular medium to quench any free dye in solution. Cells were
then plated in regular growing medium for different time
points and harvested for cell sorting using a FACS Aria
system (BD).
Cell synchronization measurements
Cells were synchronized through a double thymidine block
(18). G2N2C cells were grown to 25–30% confluence, sus-
pended in media containing 2mM thymidine, and grown for
18 h (first block). Cells were then suspended with trypsin-
EDTA (Life Technologies), divided into multiple containers,
left to grow in normal growth media for 9 h, and then incu-
bated for 17 h in media containing 2mM thymidine (second
block). Cells were released from the second block by incu-
bation in growth media without thymidine and were har-
vested at the indicated time-points.
Statistical analysis
Differences between samples were assessed by Student’s
two-tailed t-test for independent samples; p-values <0.05
were considered significant. Relative mRNA levels (in which
the first sample was arbitrarily set as one) are reported as the
results of RT-PCR in which the expression of cyclophilin A
served as housekeeping gene. All experiments were repeated
and analyzed from three to five times.
Results
BCC cells express both the activating and inactivating
thyroid hormone enzymes D2 and D3, respectively
We previously reported that BCC cells and tumors are
characterized by elevated expression of the TH inactivating
enzyme D3 (5). To probe in greater detail the mechanisms
underlying TH metabolism in BCC cells, we analyzed the
expression of other proteins related to TH metabolism,
namely, D2, THRa, THRb, MCT8, and MCT10, and com-
pared their expression with that of normal mouse primary
keratinocytes ( b SF1Supplementary Fig. S1A; Supplementary Data
are available online at www.liebertpub.com/thy). Surpris-
ingly, BCC cells showed sustained expression of D2 mRNA;
Furthermore, receptors and transporters were expressed at
slightly lower levels in BCC cells than in mouse keratino-
cytes (Supplementary Fig. S1). Since sustained D2 expression
was unexpected, we compared D2 expression in BCC cells
with its expression in solid BCC and in known D2-expressing
tissues, namely pituitary and brown adipose tissue, compared
with a ‘‘low-expressing tissue,’’ namely, skeletal muscle.
PCR analysis showed that BCC cells and tumors express
consistent levels of D2, similar to unstimulated brown ad-
ipose tissue (Fig. S1B). These data demonstrate that BCC
cells represent a complex TH-sensitive system with which
to study the intracellular regulation of TH action.
D2 and D3 depletion inversely regulate
intracellular TH availability
To address the functional relevance of D2 and D3 co-
expression in BCC cells, we genetically depleted DIO2 (D2)
or DIO3 (D3) gene expression using CRISPR/Cas9 tech-
nology. The generation of the CRISP-CTR and D3KO clones
is reported elsewhere (17). D2 was depleted using the same
CRISPR/Cas9 system used for D3-depletion (see methods
section). Four different D2KO clones were selected, and ef-
fective D2 depletion was confirmed by DNA sequencing
( b SF2Supplementary Fig. S2). To assess whether D2- and D3-
depletion affect nuclear TH availability, we transfected the
generated cells with a T3-dependent artificial promoter that
drives the luciferase gene (TRE3-Tk-Luc promoter). As ex-
pected, TH activity was reduced in D2KO cells and enhanced
in D3KO cells ( b SF3Supplementary Fig. S3A). Interestingly, the
T3 signal in D2KO cells was even lower than in normal BCC
cells (which are already characterized by an ‘‘intracellular
hypothyroid state’’). This finding shows that D3 is not the
only enzyme controlling the total thyroid signal within
these cells. Similar results were obtained by measuring the
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bAU6FIG. 1. Cell cycle progression is significantly altered in D2- and D3-
depleted cells. (A) Cell cycle distribution was measured in asynchronized
cells by flow cytometry using propidium iodide staining; the percent of
cells in each cell cycle phase is shown in a bar graph. (B) Cell cycle profile
of synchronized CTR, D2KO, and D3KO cells at 0, 3, 6, 9, and 12 h upon
release from a double thymidine block. Cells were analyzed with flow
cytometry upon propidium iodide staining. n= 3. (C) CTR, D2KO, and
D3KO cell proliferation was followed for 72 h using the carboxy-
fluorescein succinimidyl ester (CFSE) CellTraceTM Violet reagent. The
discrete peaks in this histogram represent successive generations of live,
CFSE-positive cells. The percentage of count is represented for the three
cell lines. Data are represented as mean of three experiments done in du-
plicates. Differences between CTR cells and D2KO or D3KO cells at each
time point were assessed by Student’s two-tailed t-test for independent
samples. p-Values <0.05 were considered significant.
b 4C
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expression of two TH-target genes in the skin, K10 and K14
(Supplementary Fig. S3B).
Targeted mutagenesis of D2 and D3 influences
cell proliferation
To investigate and compare the functional consequences
of genetic inactivation of D2 and D3 in BCC cells, we first
evaluated cell proliferation in three clones for each condition
(CTR, D2KO, and D3KO). Representative cell proliferation
curves of one clone for each condition showed that D2KO
cells grow faster than control cells, while D3-depletion in
D3KO cells inhibits cell growth (F2c Fig. 2A). EdU incorpora-
tion confirmed a growth advantage for the D2-depleted
cellsAU7c and a drastically decreased number of proliferative
cellsAU6c in a D3-null background (Fig. 1B). Similarly, colony
assay demonstrated that D2-depletion accelerates cell pro-
liferation, and that the opposite occurred in D3-depleted
cells (Fig. 2C). These findings indicate that deiodinases D2
and D3 exert opposite effects on cell cycle control: D2-
depletion accelerates cell proliferation, while D3-depletion
inhibits cell replication.
We also treated D2KO clones with physiological T3
concentrations to assess if D2KO-dependent increases in cell
proliferation were due to TH signal inactivation. T3 treatment
decreased the proliferation rate of D2KO cells to almost that
of CTR cells ( b SF4Supplementary Fig. S4A). Analogously, we
cultured D3KO cells in medium containing TH (normal se-
rum) and in TH-deprived medium (charcoal stripped, CH).
TH deprivation rapidly rescued the slow cycling profile of
D3KO cells, which indicates that the reduced proliferation of
D3KO cells depends on increased intracellular TH concen-
tration (Supplementary Fig. S4B).
TH modulation by D2 and D3 affects cell
cycle progression
We examined the cell cycle phase distribution in asyn-
chronized cells using flow cytometry. D3 depletion decreased
S-phase cells and increased the population of G1-phase and
FIG. 2. Selective type 2 and type 3 deiodinase (D2, D3) mutagenesis inversely regulates cell proliferation. (A) Cell
growth curves of CRISPR/Cas9 control cells (CTR), and D3 knockout (D3KO) and D2KO cells. The means of three
independent experiments, each conducted in triplicate, are shown. (B) Edu/Dapi staining performed to detect proliferating
cells. (C) Clonogenic assay of CRISP-CTR, D3KO, and D2KO cells grown for 3 and 5 days as indicated; representative
images of petri dishes are shown. Statistical significant differences were evaluated by two-way analysis of variance with the
Bonferroni post-test to compare all data from D3KO and D2KO clones to those from CRISP-CTR at each time point.
4Cc
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G2-phase cells (Fig. 2A); D2KO cells had a reduced number
of G2-phase cells. To gain further insight into the effects of
D2 and D3 depletion on cell cycle progression, we analyzed
this process in S-phase synchronized cells by blocking the
cell cycle with double-thymidine block and by forcing the
cells to reenter the cell cycle by replacing thymidine in the
medium. Cells were collected at different time points after
thymidine removal. FACS analysis demonstrated that control
cells recovered after thymidine block and that 37% of cells
were in S-phase 6 hours after thymidine removal. Interest-
ingly, D2-depleted cells divided more rapidly, and 73% of
cells were in S-phase 6 hours after thymidine removal
(Fig. 1B,SF5c Supplementary Fig. S5). On the contrary, the pro-
portion of S-phase cells was much lower in the D3KO pop-
ulation (16%) than in control cells, with a consequent shift
toward the G1 and G2 phases of the cell cycle. These data
suggest that cell cycle progression of D3KO cells is drasti-
cally compromised. As a complementary approach, we used a
fluorescence-based method for tracing the dividing cells.
Cells were labeled with a fluorescent dye (CFSE) able to
mark live cells so that when they divide, the daughter prog-
eny receives approximately half the fluorescence of the par-
ent. After labeling, cells were harvested at different time
points to measure the dye incorporation by FACS analysis.
Figure 2C shows that D2KO cells retained the dye for a
shorter time compared with CTR cells, while D3KO cells
were the longest retaining cells, thus implicating slower
replication timing for these cells.
To determine the biochemical changes underlying these
altered cell cycle profiles, we examined the cyclin D1 ex-
pression profile. Thymidine-treated cultures were released
from thymidine block at different time points, and total ly-
sates were analyzed for cyclin D1 by Western blotting
( b F3Fig. 3A, B). After synchronization, cyclin D1 increased
more rapidly in D2KO cells than in control cells. Con-
versely, cyclin D1 levels were consistently very low in
FIG. 3. CyclinD1 expression reflects alterations in cell cycle in D2- and D3-depleted cells. (A) Cyclin D1 protein levels
from synchronized CTR, D2KO, and D3KO cells at 0, 3, 6, 9, and 12 h upon release from a double thymidine block were
measured by Western blotting. (B) Band intensities of Cyclin D1 and ERK levels were quantified by densitometric analysis
with the ImageLab software and the levels of Cyclin D1/ERK are represented during the different time points. (C) Band
intensity of the levels of cyclin D1/ERK from the Western blot reported in A and relative to time 0. (D) Basal levels of
cyclin D1 mRNA from CTR, D2KO, and D3KO cells were measured by real-time PCR.
4Cc
6 MIRO ET AL.
THY-2016-0532-ver9-Miro_1P.3d 02/10/17 2:45pm Page 6
FIG. 4. Elevated TH levels in D3KO cells enhance basal apoptosis. (A) Flow cytometry detection of phosphatidylserine
exposure analyzed with annexin V and propidium iodide (PI). Flow cytometry showed the increased population at early
apoptosis (annexin V+/PI-) and at late apoptosis (annexin V+/PI+) in D3-depleted clones. (B) Apoptosis was measured with
a TUNEL assay in CTR, D2KO, and D3KO clones. The blue signal represents DAPI-positive cells and the red signal
represents TUNEL-positive cells. Percentages of TUNEL/DAPI-positive cells in each sample are represented in the graph
bar. (C) PARP and Bcl-2 levels were measured by Western blotting in CRISP CTR, D3KO, and D2KO clones. Band
intensity was quantified by densitometric analysis with the ImageLab software. (D)Western blot analysis of PARP cleavage
in D2KO and CTR cells treated with 2.5 and 10 lM doxorubicine. Ratio of cleaved versus uncleaved PARP is represented
by bars.
4Cc
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D3KO cells and increased slightly only nine hours after
synchronization (Fig. 3A, B). Basal levels of cyclin D1 were
lower in D3KO cells and higher in D2KO cells than in
controls (Fig. 3C). A similar expression profile was ob-
served at mRNA level (Fig. 3D). Taken together, these data
indicate that concerted D2 and D3 action regulates S-phase
entry and cyclin D1 expression.
D2-depletion protects BCC cells from cell death
Lastly, we analyzed the effects of D2 and D3 depletion on
cell death. Annexin V incorporation and FACS analysis
demonstrated that while apoptotic cells represent 4.4% of the
control cell population, apoptosis was reduced to 1.5% in
D2KO cells and increased to 14.8% in D3KO cells (F4c Fig. 4A).
TUNEL assay confirmed this result (Fig. 4B). PARP ex-
pression and cleavage confirmed that D2KO cells have a
reduced basal apoptotic rate versus control cells (Fig. 4C).
Interestingly, D2-depletion protected BCC cells also from
doxorubicin- and tunicamicin- (data not shown) induced
apoptosis, thus revealing a hitherto unrecognized role of
hypothyroidism as an anti-apoptotic condition (Fig. 4D).
Discussion
The goal of this work was to dissect the role of deiodinases
D2 and D3 in the regulation of intracellular TH signaling and
their relative contribution to BCC cell tumorigenesis. Using a
system of genetic depletion of the deiodinases D2 and D3, we
generated D2KO and D3KO BCC cells, which have reduced
and enhanced nuclear TH action respectively. The most
prominent feature of these cells was a drastic alteration in cell
proliferation rate, which reinforces the concept that TH plays
a critical role in controlling cell proliferation. Given the
pleiotropic roles played by TH in cell differentiation, growth,
and metabolism, it is not surprising that the effects of TH on
cell proliferation differ widely depending on the cellular
context (19). Differential interaction with co-activator and
co-factors, tissue-specific expression of different receptor
isoforms, and the presence or absence of additional chro-
matin modifiers can explain the context-related effects of TH
on cellular proliferation.
The BCC model is an example of high D3 expression
within a tumor highly sensitive to TH (5,7,17). We have
demonstrated that both treatments of BCC, with topical T3 or
intracellular enhancement of the T3 signal by D3-depletion,
affect BCC tumorigenesis by modulating multiple oncogenic
signals, among them Shh/Gli2 (5) and miR21 (AU8c 20). Conse-
quently, we used the BCC cell line to unravel the molecular
mechanisms by which TH interferes with the cell cycle ma-
chinery in a tumoral environment. Interestingly, while D3was
hitherto considered the deiodinase most frequently linked to
tumoral transformation (19), we found robust levels of D2, the
TH-activating enzyme, in BCC cells. Why is D2 expressed in
BCC cells and what is its role in this tumoral context? We do
not have a complete answer to this question, but the present
study and our preliminary data indicate that BCC and colon
cancer tumors (data not shown here) express D2 mRNA and
protein besides D3, which implicates a possible role of D2 in
tumorigenesis. Furthermore, other preliminary data on dual
D2-D3 expression in BCC indicate that the two enzymes are
partially co-expressed during tumor formation, with D3 being
expressed in an early stage of tumorigenesis and D2 appearing
thereafter (data not shown). It is conceivable that in some
cellular contexts the presence of both activating and in-
activating TH mechanisms is a means with which to rapidly
customize the TH signal as necessary. The regulator of D2
expression in BCC and in the tumorigenesis in general is not
known. Preliminary data from in vitro transfections in BCC
cells indicate that none of the well-known inducers of BCC
tumorigenesis (i.e., Gli2, b-catenin, and miR21) drive D2
expression in BCC. Consequently, further studies are required
to clarify the regulation of D2 in vivo in BCC.
The most obvious phenotype of the generated deiodi-
nase knockout cells was a drastic variation in cell prolif-
eration. D2KO cells have low TH nuclear activity, as
demonstrated by transactivation studies and the levels of
TH target gene expression, and consequently represent a
model of a ‘‘hypothyroid’’ condition. These cells are
characterized by a high proliferation rate and by a high
proportion of S-phase cells. Conversely, D3KO cells are
slowly cycling cells and are characterized by increased
nuclear TH activity when compared with control cells.
These results point to a model in which TH slows the
proliferation rate in the BCC context.
Studies in both synchronous and asynchronous cells
indicate that variations of the proliferative rate induced by
deiodinase depletion are associated to the proportion of S-
phase and to cyclin D1 expression. Cyclin D1 is a key
player in cell cycle modulation (21) and is dynamically
regulated at both transcriptional and post-transcriptional
level during the cell cycle to ensure the G1 to S progres-
sion of cells (20). Cyclin D1 is also a TH target in several
cell contexts (19). However, the transcriptional regulation
of cyclin D1 by TH is dynamic and highly variable de-
pending on the context. Breast cancer is an example of a
tumor in which the TH-TRb complex reduces tumorigen-
esis by down-regulating cyclin D1 expression (22). Ad-
ditionally, TRb suppresses estrogen-dependent tumor
growth of human breast cancer cells (23). Recently, it was
suggested that the mechanism by which TRb acts as tumor
suppressor is via up-regulation of the nuclear receptor co-
repressor 1 (NCOR1) and suppression of invasion, tumor
growth, and metastasis in human hepatocarcinomas (24).
Also in neuroblastoma cells, over-expression of TRb in-
hibits the transcriptional response of the RAS/mitogen-
activated protein kinase/ribosomal-S6 pathway, thereby
suppressing growth (25). Similarly, overexpressed TRb in-
hibited the AKT-mTOR-p70S6K pathway in human follicu-
lar thyroid cancer cells (26). Overexpression of cyclin D1
mRNA was detected in Thrb PV/PV mice in which the Thrb
gene was mutated by an insertion leading to a frame-shift of
TRb1 and a total loss of triiodothyronine (T3) binding ability.
The molecular mechanism by which this TRb mutation in-
creases cyclin D1 expression in Thrb PV/PV mice was found to
be due, at least in part, to the loss of the negative regulation
of cyclin D1 promoter activity by wild-type receptor (27). On
the other hand, there are many examples showing that TH
and its receptors exert a positive effect on cell proliferation
(28,29). Therefore, to better contextualize the transcriptional
role of TH in cyclin D1 expression, we measured the levels
of cyclin D1 mRNA and protein in synchronized BCC cells
(5). Our data demonstrate that TH attenuation in D2KO cells
potentiates the expression of this crucial cyclin, whereas the
opposite occurs in D3KO cells.
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Besides regulating cell cycle progression, modulation of
T3 by D2 and D3 also affects BCC cell survival. Using our
deiodinase loss-of-function BCC cell models, we evaluated
the effects of T3 on apoptosis, and obtained evidence that T3
plays a pro-apoptotic role in BCC cells. Indeed, lower T3
levels in D2KO cells reduced basal apoptosis as measured by
annexin V incorporation and FACS analysis, but they were
also associated with stronger resistance to the apoptotic
stimuli of doxorubicine and tunicamicine.
In conclusion, our results demonstrate that D2 and D3 are
simultaneously expressed in BCC cells and that their action
fine-tunes the TH signal. Manipulation of D2 or D3 dra-
matically affects the proliferative potential of BCC cells. Our
results are compatible with the recent finding that precise
regulation of the TH-dependent landscape of gene expression
is essential in a vast range of biological processes, namely,
embryonic development, tissue repair, and tumorigenesis (4).
From a broad perspective, these novel concepts expand the
use of deiodinases as a tool with which to interfere in diverse
pathophysiological contexts in order to adapt the TH signal in
a tissue-specific fashion.
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SUPPLEMENTARY FIG. S1. Expression of Dio2, Dio3, THRa, THRb, MCT8, and MCT10 in BCC cells and wild-type
(WT) keratinocytes. mRNA expression levels were assessed by real-time quantitative reverse transcription–PCR in BCC
cells and in WT keratinocytes. mRNA levels were normalized to those of the cyclophilin A gene. mRNA expression levels
in BCC cells was calculated by the 2-DDCt method relative to WT keratinocytes, in which expression is reported as 1.
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SUPPLEMENTARY FIG. S2. Mutagenesis of D2 in BCC cells. Schematic representation of the DIO2 locus. Four
clones are compared to WT BCC cells. The red arrow indicates the selected clone.
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SUPPLEMENTARY FIG. S3. Mutagenesis of D2 and D3 expression drastically alters intracellular triiodothyronine (T3)
signaling. (A) Control (CTR), type 2 deiodinase knockout (D2KO), and D3KO cells were transfected with the artificial T3-
responsive promoter TRE3-TK-Luc and cells were analyzed for luciferase activity. The results are shown as
means – standard deviation of the luciferase/renilla (LUC/Renilla) ratios from at least three separate experiments, performed
in duplicate. *p < 0.05, **p< 0.01, ***p < 0.001. (B) K10 and K14 mRNA expression levels were assessed by real-time
quantitative reverse transcription–PCR in the CTR, D2KO, and D3KO clones. *p < 0.05.
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SUPPLEMENTARY FIG. S4. Manipulation of T3 levels rescues the D2KO and D3KO phenotype. (A) Cell growth
curves of D2KO cells cultured with normal serum with or without the addition of 3 nM T3. (B) CTR and D3-KO clones
were plated in 60 mm dishes with 10% fetal bovine serum (FBS) (normal serum, NS) or with 10% Ch. St-FBS (charcoal
stripped serum, CH). On alternative days, cells were harvested in PBS and counted. The graph shows the means of two
independent experiments, each conducted in triplicate.
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Supplementary Table 1. List of Oligonucleotides
Oligonucleotides used for real-time PCR
Gene Forward primer (5¢/ 3¢) Reverse primer (5¢/ 3¢)
Cyclophilin A CGCCACTGTCGCTTTTCG AACTTTGTCTGCAAACAGCTC
Dio2 CTTCCTCCTAGATGCCTACAAAC GGCATAATTGTTACCTGATTCAGG
Dio3 CCGCTCTCTGCTGCTTCAC CGGATGCACAAGAAATCTAAAAGC
Thra1 CCTGGATGACACGGAAGTGGCT GGGCACTCGACTTTCATGTG
Thrb1/2 CACAGGGTACCACTATCGCTGC CAGCACCAAGTCTGTTGCCATGC
Mct8 TTCGGCTGGATAGTGGTGTTTGCA ATCATGCCCATAGCGAGGGCTC
Mct10 CCATCGTGAGTGTCTTCACGGACAT GGAGCAGGATTGTGAAGACGCTGC
Kyclin D1 GCTCCTGTGCTGCGAAGTGGA TCATGGCCAGCGGGAAGACCT
Krt10 CGAGCTGGAGGGTAAAATCA CGTTGGCATTGTCAGTTGTC
Krt14 GATGTGACCTCCACCAACCG CCATCGTGCACATCCATGAC
Oligonucleotides used for genome analysis of CrispR/CAS clones
gdio3U CGACCCAAGATTTCTGGGGCA
gdio3L AGCAGAGTCTCAAGTTAGCCAGAC
Dio2_ex1U AGAGCCTGAACCTGGTCTTT
Dio2_ex1L CACACCTTCCACACCCCTAG
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AUTHOR QUERY FOR THY-2016-0532-VER9-MIRO_1P
AU1: Please note that the gene symbols in any article should be formatted as per the gene nomenclature. Thus, please
make sure that the gene symbols, if present in this article, are italicized.
AU2: Please check all author names for accurate indexing.
AU3: Please expand abbreviated institution names.
AU4: Should this indicate thyroid hormone (e.g., nuclear thyroid hormone receptors)?
AU5: Reworded to add definition of FACS. Please check wording to ensure that it is acceptable.
AU6: Figures 1 and 2 reordered/renumbered to appear chronologically in the text.
AU7: Please expand EdU.
AU8: References 20 and 21 reordered/renumbered to appear chronologically.
AU9: Expand abbreviated term/institution name AIRC.
AU10: Please add degree abbreviations (ex., MD, PhD).
THY-2016-0532-ver9-Miro_1P.3d 02/10/17 2:47pm Page 11
